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RESUMO 
 
A 15-deoxyΔ-PGJ2 (15d-PGJ2), um dos derivados do metabolismo da prostaglandina 
D2, quando aplicada na Articulação Temporomandibular (ATM) de ratos Wistar resulta em 
um potente efeito anti-inflamatório e analgésico, mediado pela ativação dos receptores 
ativados por proliferadores de peroxissoma do tipo gamma (PPARγ) com a co-participação 
dos receptores κ- e δ- opióides e ativação da via intracelular L-Arg/NO/GMPc/K+ATP. No 
entanto, o mecanismo pelo qual ocorre a interação entre estes receptores e o processo 
antinociceptivo ainda permanece desconhecido. O primeiro estudo apresentado nesta tese teve 
como objetivo elucidar os mecanismos neuroquímicos envolvidos no efeito antinociceptivo da 
15d-PGJ2 na ATM de ratos. Para este estudo foram utilizados Ratos Wistar machos, 6 a 8 
semanas, n = 4-6/grupo) e todos os experimentos foram aprovados pela Comissão de Ética no 
Uso de Animais da UNICAMP (#2532-1). Os resultados demonstraram que o pré-tratamento 
com o antagonista do receptor PPARγ (GW9662; 3 ng/ATM) bloqueou o efeito 
antinociceptivo da 15d-PGJ2 (100 ng/ATM) na dor induzida pela injeção intra-articular de 
formalina 1,5%; mas não afetou o efeito antinociceptivo induzido pelos agonistas dos 
receptores κ-opióide (U50,488; 30 µg/ATM) e δ-opióide (E6264; 10 µg/ATM). Foi avaliado 
se a ativação da via intracelular L-Arginina/NO/cGMP/K+ATP pela 15d-PGJ2 seria mediada 
pela via PI3Kɣ/AKT. No entanto, o tratamento prévio com o inibidor da PI3Kɣ (AS605240; 
30 μg/ATM) ou antagonista seletivo da AKT (AKT inibidor IV; 10 μg/ATM) não afetou a 
antinocicepção induzida pela 15d-PGJ2 na ATM. As análises de Western blot do gânglio 
trigeminal demonstraram que a 15d-PGJ2 aumentou significativamente a expressão de GRK3 
e β-arrestina.  Além disso, pelo método ELISA foi possível demonstrar que a injeção de 15d-
PGJ2 aumentou significativamente a liberação de peptídeos opióides endógenos dinorfina e β-
endorfina no tecido periarticular de animais pré-tratados com o recrutador de macrófagos 
tioglicolato 1%. Em suma, o presente estudo sugere que o efeito antinociceptivo periférico da 
15d-PGJ2 é mediado pelo PPARJ expressos nas células inflamatórias dos tecidos da ATM. 
Uma vez ativado pela 15d-PGJ2, o PPARJ induz a liberação de β-endorfina e dinorfina, que 
ativam receptores N e G opióides em neurônios sensoriais primários para induzir o efeito 
antinociceptivo. O segundo estudo teve como objetivo avaliar se o efeito antinociceptivo do 
creme com 15d-PGJ2 aplicado topicamente pode ser potencializado com a aplicação prévia 
das microagulhas em um modelo na ATM de ratos. Os resultados demonstraram que só a 
aplicação tópica do creme com 15d-PGJ2 não induz qualquer efeito antinociceptivo 
significativo em comparação com  a injeção intra-articular de 15d-PGJ2. Na sequência, os 
animais receberam a aplicação de microagulhas na pele da região da ATM, viabilizando o 
rompimento do estrato córneo da pele para aplicação do creme com 15d-PGJ2. Este tratamento 
resultou em um efeito antinociceptivo e anti-inflamatório significativo na dor induzida pela 
formalina 1,5 % na ATM de ratos. Este estudo propõe uma nova estratégia terapêutica para o 
controle de dor inflamatória na ATM que é menos invasiva e de ação periférica. 
 
Palavras-chaves: 15d-PGJ2. ATM. Nocicepção. Opióides endógenos. Microagulhas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
The 15-deoxy Δ-PGJ2 (15d-PGJ2), one of the derivatives of prostaglandin D2 
metabolism, when applied in the Temporomandibular joint (TMJ) of Wistar rats results in a 
potent anti-inflammatory and analgesic effect, mediated by activation of peroxisome 
proliferators-activated receptor gamma (PPARγ) with the co-participation of κ-and δ-opioid 
receptor and activation of intracellular pathway L-Arg/in/GMPc/K+ATP. However, the 
mechanism by which interaction occurs between these receptors and the evaluate process still 
remains unknown. The first study presented in this thesis aimed to elucidate the 
neurochemical mechanisms involved in the antinociceptive effect of 15d-PGJ2 on TMJ. For 
this study we used male Wistar rats (6 to 8 weeks old, n = 4-6/group), all experiments were 
approved by Committee on Animal Research of the University of Campinas (# 2532-1). The 
results showed that pretreatment with the PPARγ receptor antagonist (GW9662; 3 ng/TMJ) 
blocked the antinociceptive effect of 15d-PGJ2 (100 ng/TMJ) on pain induced by intra-
articular injection of 1.5% formalin; but did not affect the antinociceptive effect induced by 
the κ-opioid receptor agonists (U50,488; 30 µg/TMJ) and δ-opioid (E6264; 10 µg /TMJ). We 
evaluate if the activation of the intracellular pathway L-arginine/NO/cGMP/K+ ATP for 15d-
PGJ2 is mediated by PI3Kɣ/AKT pathway. However, pretreatment with PI3Kɣ inhibitor 
(AS605240; 30 μg/TMJ) or selective antagonist of AKT (AKT inhibitor IV; 10 μg/TMJ) did 
not affect the antinociception induced by 15d-PGJ2 on TMJ. Western blot analysis of 
trigeminal ganglion demonstrated that 15d-PGJ2 significantly increased the expression of β-
arrestin and GRK3. In addition, by ELISA method was possible to demonstrate that the 
injection of 15d-PGJ2 significantly increased the release of endogenous opioid peptide 
dynorphin and β-endorphin in the periarticular tissue from animals pretreated with 1% 
thioglycolate, macrophage cells inductor. In conclusion, the present study suggests that the 
peripheral antinociceptive effect of 15d-PGJ2 is mediated by PPARγ expressed in 
inflammatory cells of TMJ tissues. Once activated by the 15d-PGJ2, PPARγ induces the 
release of β-endorphin and dynorphin, which activate κ/δ opioid receptors in primary sensory 
neurons to induce the antinociceptive effect. The second study aimed to assess whether the 
antinociceptive effect of 15d-PGJ2 cream applied topically can be enhanced with the prior use 
of microneedles on a TMJ model. The results showed that only the topical application of 
cream with 15d-PGJ2 does not induce any significant antinociceptive effect in comparison 
with intra-articular injection of 15d-PGJ2. Following the animals were received the 
microneedles application on the skin in the TMJ region enabling disruption of the stratum 
corneum for the application of the cream with 15d-PGJ2. This treatment resulted in a 
significant antinociceptive and anti-inflammatory effect on 1.5% formalin-induced 
nociception in rats TMJ. This study proposes a new therapeutic strategy for the control of 
TMJ inflammatory pain in less invasive and peripheral action. 
 
Keywords: 15d-PGJ2. TMJ. Nociception. Endogenous opioids. Microneedles. 
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1 INTRODUÇÃO 
A Disfunção Temporomandibular (DTM) é uma condição na qual há uma 
desarmonia no sistema estomatognático, podendo ocorrer envolvimento e prejuízo nos 
músculos mastigatórios, na articulação temporomandibular (ATM) propriamente dita, ou em 
ambos (Leeuw, 2008). A etiologia da DTM é considerada complexa e multifatorial por 
envolver fatores de origem biológica, psicológica e sistêmica. É caracterizada pela presença 
de sinais e sintomas como ruídos articulares, redução da amplitude ou alteração dos 
movimentos mandibulares, limitações funcionais, dores na musculatura mastigatória, na 
região pré-auricular e/ou na própria articulação (Kumar et al., 2015).  A DTM e a dor 
orofacial aparecem com alta prevalência na população, sendo que os sinais e sintomas estão 
presentes em até 86% da população ocidental (Kumar et al., 2015). O controle da dor é a 
primeira meta no tratamento da DTM (Cairns, 2010; Sessle, 2011).  
A dor é um dos sinais clássicos de processo inflamatório, apresentando como 
denominador comum a sensibilização dos receptores nociceptivos dos aferentes primários. 
Decorrente de estímulos inflamatórios ou lesões teciduais, a liberação de citocinas e 
quimiocinas pró e anti-inflamatórias desencadeiam a liberação de prostanóides e aminas 
simpatomiméticas, que por sua vez atuam diretamente nos nociceptores causando a 
hipernocicepção, resultado da redução do limiar de excitabilidade devido à modulação de 
canais de sódio voltagem-dependentes (Verri et al, 2006).   
A evolução natural da dor é a remissão, porém, em decorrência da ativação de 
várias vias neuronais de modo prolongado, o caráter da dor pode se modificar evoluindo em 
muitos casos para a cronificação. A dor crônica acomete, em todo o mundo, cerca de 100 
milhões de indivíduos e aproximadamente 14% da dor crônica está relacionada às articulações 
e ao sistema musculo esquelético (Gagliese e Melzack, 2003). É um sério problema de saúde 
pública, e pode ter consequências na qualidade de vida dos pacientes.  
A DTM se manifesta através de sintomatologia variada, sendo assim estratégias 
para o seu controle são muitas vezes insatisfatórias. Dentro deste contexto, o desenvolvimento 
de novas condutas terapêuticas mais eficazes é de grande interesse para pacientes e clínicos 
(Cairns, 2010). 
Os receptores nucleares estão dentre as mais importantes moléculas envolvidas na 
regulação intracelular, pois participam na transmissão de diferentes sinais internos e externos 
para a regulação de programas genéticos (Schote et al., 2007). A regulação e a seletividade 
promovida pelos receptores nucleares estimulam a intensa pesquisa que vêm sendo realizada 
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na tentativa de decifrar os eventos moleculares que promovem a sua capacidade de regulação 
da transcrição e assim, descobrir as regras que definem seu controle, sobre as interações 
proteína-proteína e proteína-DNA, abrindo possibilidades para o desenvolvimento de drogas 
mais eficientes com valores terapêuticos superiores (Novac e Henzel, 2004).  
Dentre os receptores nucleares, os receptores ativados por proliferadores de 
peroxissoma (PPARs) são fatores de transcrição ligantes dependentes que regulam a 
expressão do gene - alvo pela ligação a específicos PPREs (elementos responsivos aos 
proliferadores de peroxissoma) situados em sítios regulatórios de cada gene (Wahli et al., 
1995). Os ativadores PPAR inibem a ativação de genes de resposta inflamatória por interferir 
negativamente nas vias de sinalização, e exercem essas atividades anti-inflamatórias em 
células como monócitos-macrófagos, endoteliais, epiteliais e células musculares lisas em que 
o receptor é expresso e seus ligantes estão entre os mais promissores compostos atualmente 
estudados (Scirpo et al., 2015; Chen et al., 2015). 
O receptor de ativação de proliferação do peroxissomo-γ (PPARγ) (Escher e 
Wahli, 2000) tem recebido considerável atenção tanto pelo seu papel como sensor lipídico 
(Lehrke e Lazar, 2005), quanto pelo seu papel como regulador de condições inflamatórias e 
de injúrias no SNC (Morgenweck et al., 2010). 
A 15-deoxyΔ-PGJ2 (15d-PGJ2) um dos derivados do metabolismo da 
prostaglandina D2, é um ligante natural para PPARγ (Schoonjans et al., 1997; Ricote et al., 
1998) o que sugere que esta molécula possui um importante papel na regulação da reação 
inflamatória in vivo. 
Outro aspecto a ser considerado é que agonistas do PPAR-γ apresentam potente 
efeito neuroprotetor em modelos animais com injúrias agudas no SNC (Sundararajan et al., 
2005; Zhao et al., 2005; Pereira et al., 2006; Collino et al., 2006; Tureyen et al., 2007; Park et 
al., 2007; McTigue et al., 2007; Hyong et al., 2008). Tem sido demonstrado que, assim como 
na injúria nervosa periférica, a expressão dos PPAR-γ aumenta significativamente em 
modelos animais de isquemia cerebral, suportando a idéia de que injúrias nos tecidos nervosos 
alteram a sinalização neural dos PPAR-γ (Victor et al., 2006). Complementando estes dados, 
a literatura sugere que a ativação farmacológica dos PPAR-γ no cérebro e na medula inibe 
rapidamente a transmissão dos estímulos nociceptivos induzidos pelos mediadores 
inflamatórios, sugerindo que os PPAR-γ são importantes moduladores da dor (Morgenweck et 
al., 2010). Suportando estes dados, estudos prévios demonstraram a presença PPAR-γ nas 
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terminações periféricas dos aferentes somáticos e evidenciam o papel destes receptores na 
modulação da dor (Victor et al., 2006). 
Em um estudo de nosso grupo de pesquisa foi demonstrado que a ativação dos 
PPAR-γ na ATM induz um potente efeito anti-inflamatório e antinociceptivo periférico com a 
co-participação dos receptores capa e delta opióides através da ativação da via intracelular L-
Arg/NO/GMPc/K+ATP (Pena-dos-Santos et al., 2009).  
Os receptores opióides pertencem a uma superfamília de receptores acoplados à 
proteína G e são observados em áreas correlacionadas com a percepção da dor (lâminas I, II e 
V), a modulação do comportamento afetivo (amígdala, hipocampo, locus coeruleus e córtex) e 
a regulação do sistema nervoso autônomo e funções neurovegetativas (bulbo e hipotálamo) 
(Bodnar, 2015). A ativação dos receptores opióides através de agonistas endógenos (peptídeos 
opióides) e exógenos apresentam inúmeras consequências: inibição da atividade da 
adenilciclase levando a uma redução da concentração intracelular de monofosfato cíclico de 
adenosina (cAMP), a abertura dos canais de K+, causando a hiperpolarização do neurônio 
nociresponsivo, com consequente redução da excitabilidade e o bloqueio da abertura dos 
canais de Ca++ voltagem – dependentes, inibindo a liberação do glutamato e da substância P 
pelos terminais aferentes primários. Estes mecanismos explicam o bloqueio opióide da 
liberação de neurotransmissores e na transmissão da dor em várias vias neuronais (Zhang e 
Bao, 2015). Os peptídeos opióides são os neurotransmissores e neuromoduladores naturais da 
dor constituindo o sistema de controle endógeno da dor e consistem de três grupos principais: 
encefalinas, beta-endorfinas e dinorfinas e podem ser liberados após estímulos dolorosos, 
agindo em vários receptores opióides, mu (μ), delta (δ) e kappa (κ), de modo a suprimir as 
respostas nociceptivas na periferia, na medula espinhal e no cérebro. O sistema de modulação 
opióide não é exclusivamente central; apresenta componentes periféricos, sendo encontrados 
receptores opióides nos macrófagos, mastócitos, nos gânglios trigeminais e espinhais, e nas 
fibras sensitivas (Kirkpatrick et al., 2015). 
Os receptores opióides ao se ligarem a peptídeos opióides endógenos, ativam a 
proteína G acoplada nos receptores desencadeando respostas intracelulares. A região C-
terminal do receptor é fosforilada por ação de quinases de receptores acoplados a proteína G 
(GRKs) (Lefkowitz e Shenoy, 2005). As GRKs foram inicialmente descritas como uma 
família de serina/treonina quinases. É composta por sete isoformas divididas em três 
subfamílias de acordo com sua homologia estrutural. GRK1 e GRK7 são encontrados apenas 
na retina. GRK4, GRK5 e GRK6 não são ativados pela proteína G subunidade βγ. GRK2 e 
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GRK3 são ativados pela proteína G subunidade βγ e são transportadas do citosol para a 
membrana por esta subunidade. GRK3 é expressa em várias regiões do cérebro incluindo 
córtex e hipocampo sugerindo um papel importante na modulação da neurotransmissão nestas 
regiões (Rao et al., 2009). A fosforilação dos resíduos de aminoácidos na porção C-terminal 
dos receptores serve de sinalização para ligação de proteínas da família das β-arrestinas que, 
uma vez ligadas ao receptor, impedem a interação do mesmo com as unidades 
heterotriméricas das proteínas G, mantendo o receptor desacoplado e caracterizando assim a 
dessensibilização desse receptor (Premont e Gainetdinov, 2007). 
Estudo demonstrou que morfina, um ligante de receptor opióide, além de produzir 
efeitos centrais no cérebro, também pode induzir a antinocicepção periférica, e que este efeito 
é mediado por meio de hiperpolarização neuronal através da via NOS/NO/K+ATP, que requer 
estimulação inicial por fosfatidilinositol-3-quinase/serina-treonina quinase (PI3K/AKT). Foi 
demonstrado também que a via L-Arginina/ON/cGMP/K+ATP medeia o efeito 
antinociceptivo da 15d-PGJ2 (Pena-dos-Santos et al. 2009). 
A síntese de óxido nítrico (ON) se realiza por ação de uma enzima, a óxido nítrico 
sintetase (ONS) a partir do aminoácido L-arginina que produz ON e L-citrulina, necessitando 
da presença de dois cofatores, o oxigênio e o fosfato dinucleótido adenina nicotinamida 
(NADPH). Atualmente são conhecidas três formas de ONS, duas denominadas constitutivas 
que podem ser ativadas pela entrada de Ca2+ intracelular (cONS) com ligação a calmodulina, 
que são a endotelial e a neuronal, as quais sintetizam ON em condições normais, e a 
independente do cálcio (iONS) e dependente de fosforilação pelas quinases PI3K/AKT 
(Takata et al., 2011). As PI3Ks são enzimas responsáveis pela transdução de sinais 
intracelulares, desempenhando papel na regulação da proliferação e migração celular, na 
sobrevivência da célula, na resposta inflamatória, na expressão gênica, no metabolismo 
celular, nos rearranjos do citoesqueleto e no fluxo de cálcio. As vias de sinalização celular 
relacionadas ao PI3K desempenham papel importante na patogênese das doenças que 
apresentam componente inflamatório, tais como câncer, infarto do miocárdio, aterosclerose, 
lesão por isquemia e sépsis. Evidências recentes indicam que a via de sinalização PI3K/AKT 
pode representar um mecanismo compensatório com objetivo de limitar os eventos pró-
apoptóticos e pró-inflamatórios em resposta ao estímulo séptico (Cidado e Park, 2012). 
A dor decorrente de condições da DTM é geralmente tratada com opióides e 
agentes que inibem a resposta imune, tais como corticosteroides, ou moduladores da cascata 
inflamatória, por exemplo, anti-inflamatórios não esteroidais (Hersh et al., 2008). Essas 
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drogas são associadas com efeitos adversos significativos e riscos com o uso a longo prazo. O 
desenvolvimento de formulações para aplicação na pele é uma estratégia interessante para 
transportar fármacos representando uma alternativa para superar aspectos indesejados 
relacionados às características farmacocinéticas e farmacodinâmicas dos fármacos. No 
entanto, a pele apresenta camadas que formam uma barreira à penetração de fármacos. 
A pele humana é um órgão altamente especializado, estruturado em três camadas 
interdependentes, a epiderme, derme e hipoderme. O estrato córneo (SC), a camada mais 
externa da epiderme, funciona como barreira contra a difusão de substâncias e constitui o 
principal obstáculo à penetração das moléculas que entram em contato com a superfície da 
pele. Estruturalmente o SC é formado por corneócitos (queratinócitos diferenciados) 
incorporados em uma estrutura lamelar cristalina altamente organizada de matriz lipídica, 
criando uma barreira física à penetração de substâncias (Barry, 2004; Jensen e Proksch, 
2009).  
Os métodos físicos para promover a permeação cutânea envolvem a aplicação de 
técnicas para liberar fármacos através da pele e/ou alterar diretamente o órgão, modificando 
sua propriedade de barreira. Uma alternativa adicional para promoção da permeação cutânea 
vencendo a barreira do estrato córneo é o uso de microagulhas que são pequenas agulhas 
utilizadas para perfurar o tecido, rompendo sua função de barreira, e facilitando assim a 
entrada de fármacos através dele. Gerstel e Place demonstraram pela primeira vez um sistema 
de microagulhas em uma patente de 1976. O primeiro estudo para demonstrar o uso de 
microagulhas não foi publicado até 1998 (Henry et al., 1999), e desde então matrizes de 
microagulhas feitas de silicone, metal, aço inoxidável ou titânio têm sido relatadas com 
inúmeras vantagens, dentre elas: redução de dor e trauma tecidual durante a inserção (elas são 
conhecidas por serem indolores); técnica minimamente invasiva; diminuição da probabilidade 
de infecção no local da inserção, aumento significativo do transporte de drogas através da 
pele, especialmente compostos grandes e hidrofílicos (Nava-Arzaluz et al., 2012). 
Uma matriz de microagulhas contém muitas agulhas de tamanho micrométrico 
que podem atravessar a barreira do SC para atingir as camadas mais profundas da pele 
(Prausnitz, 2004) e criar uma via de transporte grande o suficiente para proteínas e 
nanopartículas, mas pequena o suficiente para evitar a dor (Henry et al., 1999). 
Dentro deste contexto, considerando o potencial uso terapêutico da 15d-PGJ2 nas 
condições dolorosas relacionadas ao processo inflamatório e a busca por metodologias menos 
invasivas de administração de fármacos, nos levou a realizar dois estudos. No primeiro estudo 
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tivemos como proposta avaliar os mecanismos neuroquímicos envolvidos no efeito 
antinociceptivo da 15d-PGJ2 na ATM de ratos baseado em três hipóteses: (1) A ativação do 
PPARγ pela 15d-PGJ2 desencadeia uma resposta sinérgica com os receptores opióides capa e 
delta através da ativação da via de sinalização intracelular PI3Kγ/AKT – mediadora da via 
antinociceptiva do óxido nítrico (NO); (2) A ativação do PPARγ pelo agonista 15d-PGJ2 
induz resposta antinociceptiva através da liberação de opióides endógenos por células satélites 
no gânglio trigeminal, os quais atuam ativando os receptores opióides neuronais capa e delta 
locais; e (3) A ativação do PPARγ pela 15d-PGJ2 diminui a expressão da GRK3 e β-arrestina 
aumentando a atividade dos receptores capa e delta opióides na ATM (Artigo 1). No segundo 
estudo, utilizamos um sistema de microagulhas associadas a um creme de 15d-PGJ2 visando à 
aplicação tópica deste fármaco na região da ATM e consequentemente o desenvolvimento de 
uma opção terapêutica mais segura e com melhor adesão pelos pacientes na clínica 
odontológica (Artigo 2). 
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ABSTRACT 
We have previously demonstrated that peripheral administration of 15d-PGJ2 in 
the Temporomandibular joint (TMJ) of rats can prevent nociceptor sensitization, and that this 
antinociception effect is mediated by proliferator-activated receptor-J (PPAR-J), and N- and G- 
opioid receptors. However, the mechanism that underlies the signaling of PPAR-J (upon 
activation by 15d-PGJ2) to induce antinociception, and how the opioid receptors are activated 
via 15d-PGJ2 are not fully understood. Therefore, in this study we sought to better understand 
the role of opioid receptors in the antinociceptive effect of 15d-PGJ2.  Pretreatment with an 
intra-TMJ injection of the PPAR-J antagonist GW9662 (3 ng/TMJ) blocked the 
antinociceptive effect of  15d-PGJ2 in formalin-induced pain behaviour in the TMJ of rats, but 
did not affect the antinociceptive effect induced by  N- and G-opioid receptor agonists. 
Because 15d-PGJ2 requires N- and G-opioid receptor activation, but is not a ligand for them, 
this result suggested that PPAR-J activation by 15d-PGJ2 must mediate release of endogenous 
opioid peptides to activate N- and G-opioid receptors. We also evaluated if the activation of 
the intracellular L-Arginine/NO/cGMP/K+ATP pathway by 15d-PGJ2, is mediated by 
PI3Kɣ/AKT pathway, which has recently been implicated in opioid-receptor activation. 
However, we found that pretreatment with an intra-TMJ injection of the inhibitor of PI3Kɣ 
(AS605240) or AKT inhibitor did not affect the 15d-PGJ2-induced antinociception. Western 
blot analysis demonstrated that 15d-PGJ2 significantly increased the expression of G-protein 
receptor kinase type 3 (GRK3) and β-arrestin in the trigeminal ganglia, which cause N- and G-
opioid receptor desensitization and internalization (after the receptors have been activated). In 
addition, intra-TMJ injection of 15d-PGJ2 (100 ng/TMJ) significantly increased the release of 
endogenous opioid receptor peptides dynorphin and β-endorphin in the periarticular tissue of 
animals pretreated with the macrophage-inductor thioglycollate (1%, 30 µl/TMJ/day for 3 
days). The data presented supports the hypothesis that peripheral antinociceptive effect of 
15d-PGJ2 is mediated by PPARJ expressed in the inflammatory cells of TMJ tissues. Once 
activated by 15d-PGJ2, PPARJ induces the release of β-endorphin and dynorphin, which 
activates N- and G-opioid receptors in primary sensory neurons to induce the antinociceptive 
effect. 
Keywords: 15d-PGJ2, inflammation, nociception, endogenous opioids peptides, 
pain, temporomandibular joint  
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1. INTRODUCTION 
Inflammation of orofacial tissues is the most common cause of many orofacial 
pain conditions, including temporomandibular disorders (TMDs), and in many cases it leads 
to chronic orofacial pain [1, 2]. Relieving temporomandibular joint (TMJ) pain is a challenge 
since TMDs involve deep tissues, making it difficult to target the trigeminal neural system [1, 
2]. Traditionally, medications such as non-steroidal anti-inflammatory drugs, corticosteroids, 
muscle relaxants and opiates have been used to treat TMJ pain; however, evidence supporting 
their effectiveness is lacking [1]. It has been suggested that the general clinician must 
therefore adopt an evidence-based approach for the management of orofacial pain [3]. At the 
same time, it is important to investigate and develop other pharmacological interventions to 
treat TMJ pain. 
We have investigated 15-deoxy'-12,14-prostaglandin J2 (15d-PGJ2) as a 
pharmacological agent to alleviate TMJ pain in a rat model [4, 5, 6, 7] . 15d-PGJ2, is a 
cyclopentenone prostaglandin (PG) that is formed following the dehydration and 
isomerization of PGJ2, a metabolite of PGD2. The presence of αβ-unsaturated carbonyl 
functionalities in the 15d-PGJ2 molecule contribute to a wide array of biological activities in 
many cellular systems [8]. Some of the known biological activities of 15d-PGJ2 are related to 
the observation that this compound activates peroxisome proliferator activated receptor-J 
(PPAR-J) [9, 10]. PPAR-J is a member of the nuclear receptor superfamily and a ligand-
activated transcription factor [11] with pleiotropic effects on adipocyte differentiation, 
glucose homeostasis, lipid metabolism, growth, and inflammation [12]. PPAR ligands, such 
as 15d-PGJ2, represent a promising therapeutic strategy for inflammatory diseases [13, 14, 15, 
16, 17, 18], especially when inflammatory pain [4, 5, 6, 7, 17] and neural damages [18, 19, 
20, 21, 22, 23, 24] are involved.  
We have previously demonstrated that peripheral administration of 15d-PGJ2 in 
the TMJ can prevent nociceptor sensitization, and that this antinociception effect is abolished 
when PPAR-J [4, 5, 6], or N-opioid receptor, or the G-opioid receptor is blocked [4]. These 
results suggest the role of N/G opioid receptors in the antinociceptive effect of 15d-PGJ2. 
However, the mechanism that underlies the signaling of PPAR-J (upon activation by 15d-
PGJ2) to induce antinociception, and how the opioid receptors are activated via 15d-PGJ2 are 
not fully understood. Therefore, in this study we sought to better understand the role of opioid 
receptors in the antinociceptive effect of 15d-PGJ2. 
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Because 15d-PGJ2 is not a ligand for opioid receptors [8, 9, 12], it thus cannot 
directly activate them. Hence, we speculated that 15d-PGJ2 might stimulate production of 
endogenous opioid ligands, which can then activate opioid receptors to mediate the 
antinociception effect. It has been well established that endogenous opioid peptides, which are 
natural opioid receptor ligands, or anti-inflammatory cytokines can induce peripheral 
antinociception [26, 27]. Endogenous opioid peptides are present in leukocytes, which 
migrate into inflamed tissues. Leukocyte subpopulations of opioid peptide-containing cells 
include granulocytes, monocytes/macrophages and lymphocytes. Importantly, PPAR-J is 
found in different types of cells, including macrophage cells [28,29]. Off note, macrophages 
are also the dominant leukocyte subtype recruited to inflamed sites, and produce the most 
opioid peptides compared to other leukocytes [30]. Based on these observations, we 
hypothesized that 15d-PGJ2 activates PPAR-J expressed in the leukocytes subpopulations of 
opioid peptide-containing cells of TMJ tissues, which in turn release endogenous opioid 
peptides activating N/G opioid receptor in primary sensory neurons to produce the 
antinociception effect.  
It is also important to understand how activation of N/G opioid receptors in 
peripheral neurons leads to an antinociception effect from 15d-PGJ2. Recently Cunha et al. 
[31], found that morphine, an opioid receptor ligand, in addition to producing central effects 
in the brain, can also induce peripheral antinociception, and that this effect is mediated via 
neuronal hyperpolarization through the NOS/NO/K+ATP pathway, which requires initial 
stimulation by PI3Kɣ/AKT protein kinase B (AKT). We have also previously shown that the 
L-Arginine/NO/cGMP/K+ATP pathway mediates the antinociceptive effect of 15d-PGJ2. Thus, 
we wondered if similar to morphine, 15d-PGJ2 also requires the PI3Kɣ/AKT pathway. 
Accordingly, in this study we designed experiments to assess in greater depth the 
role of N/G opioid receptors, endogenous opioid peptides from leukocytes subpopulations of 
opioid peptide-containing cells such as resident macrophages cells, and PI3Kɣ/AKT pathway 
in the antinociceptive effect of 15d-PGJ2. 
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2. MATERIALS AND METHODS 
2.1. Animals 
This study was carried out with male Wistar rats, n=4 (200 to 300 g), housed (5 
per cage) in a temperature-controlled room (23 ± 1°C) on a 12:12 light cycle, with food and 
water available ad libitum. All animal experimental procedures and protocols were approved 
by the Committee on Animal Research of the University of Campinas (2532-1/2011) and are 
in accordance with guidelines of National Council for Control of Animal Experimentation 
(CONCEA) and International Association for the Study of Pain (IASP) guidelines for the 
study of pain in conscious animals [32].   
 
2.2. Material and reagents 
15d-PGJ2, was obtained from Calbiochem (San Diego, CA, USA). Thioglycollate 
(Fluid Thioglycollate Medium dehydrated) was obtained from DIFCO Laboratories (Detroit, 
MI, USA). N-opioid receptor antagonist Nor-binaltorphimine dihydrochloride (Nor-BNI); G-
opioid receptor antagonist N,N-diallyl-Tyr-Aib-Aib-Phe-Leu (ICI 174,864); N-opioid receptor 
agonist benzeneacetamide methanesulfonate salt (U50,488);  G-opioid receptor agonist D-
Pen2,5, p-Cl-Phe4-Enkephalin (E6264); PPARJ receptor antagonist 2 -chloro-5-nitro-N-
phenylbenzamide (GW9662);  PI3Kɣ inhibitor 5-(6-Quinoxalinylmethylene)-2,4-
thiazolidinedioneand (AS605240); AKT Inhibitor IV  trifluoroacetate salt hydrate; and an 
aqueous solution of 37% of formaldehyde were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). Formalin solution was prepared from commercially available stock formalin (an 
aqueous solution of 37% formaldehyde) further diluted in 0.9% NaCl to a concentration of 
1.5%. GW9662, ICI 174,864, AS605240 and AKT inhibitor IV were dissolved in dimethyl 
sulfoxide from Sigma-Aldrich (St. Louis, MO, USA) and resuspended in saline to reduce the 
final concentration of dimethyl sulfoxide (maximum, 0.5%). Nor-BNI; U50,488 and E6264 
were dissolved in saline. 
 
2.3. TMJ injections 
Rats were briefly anesthetized by inhalation of isoflurane and a 30-gauge needle 
was introduced into the TMJ at the moment of injection. A cannula consisting of a 
polyethylene tube was connected to the needle and also to a Hamilton syringe (50 µl). Each 
rat regained consciousness approximately 30 s after discontinuing the anesthetic [33]. In order 
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to keep the volume injected into TMJ the same in all experiments, animals received a final 
volume of 45 µl into TMJ as previously described [34]. 
2.4. Testing procedure for TMJ pain 
Nociceptive behavioral testing was performed during the light phase (between 
9:00 AM and 5:00 PM) in a quiet room maintained at 23°C [35]. Before the experiments, each 
animal was manipulated for 7 days to habituate them to the experimental manipulation. On 
the day of the experiment, each animal was individually placed in a test chamber (30 x 30 x 
30 cm wooden chamber lined with mirrors on the inside on all side, with clear glass on the 
front side) for a 15-min habituation period to minimize stress. After the TMJ injection, the 
animals were immediately returned to the test chamber for counting the behavioral 
nociceptive responses during a 45-min observation period. This response was defined as the 
cumulative total number of seconds that the animal spent rubbing the orofacial region 
asymmetrically with the ipsilateral fore or hind paw plus the number of head flinches counted 
during the observation period. Since head flinches followed a uniform pattern of 1 second of 
duration, each flinch was expressed as 1 second.  The recording time was divided into 9 
blocks of 5 minutes [33, 34]. At the conclusion of the nociceptive behavioral testing, animals 
were terminally anesthetized by isoflurane and their periarticular tissue and trigeminal ganglia 
were removed for further analyses.  
 
2.5. Experimental Design  
2.5.1. Effect of blocking PPAR-J , N-opiod, and G-opioid receptor on the 
antinociception effect of 15d-PGJ2.  (1) To confirm that 15d-PGJ2 induces antinociception in 
TMJ by activation of PPAR-J, N- and G-opioid receptors, groups of rats (4-6 per group) were 
pretreated (15 min) with an intra-TMJ injection of PPAR-γ  antagonist GW9662 (3 ng/15 
µl/TMJ) [17], or a specific inhibitor of G-opioid receptor ICI 174,864 (30 µg/15 µl/TMJ) [36] 
or, a selective N-opioid receptor antagonist Nor-BNI (200 µg/15 µl/TMJ) [34]. This was 
followed by an intra-TMJ injection of 15d-PGJ2 (100 ng/15 µl/TMJ) 15 min prior ipsilateral 
intra-TMJ injection of 1.5 % formalin (15 µl/TMJ).  (2) To study the effect of PPARJ 
activation on N- and G-opioid receptor-induced antinociception in the TMJ, animals were first 
treated with an intra-TMJ injection of PPAR-γ receptor antagonist GW9662 (3, 30 and 100 
ng/15 µl/TMJ) [13] and followed by (15 min later) the selective N-opioid receptor agonist 
U50,488 (30 µg/ 15 µl/ TMJ) [34], or the selective G-opioid receptor agonist E6264 (10 µg/15 
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µl/TMJ) [37]. Another 15 min later, 1.5% formalin (15 µl/TMJ) was injected to evaluate 
antinociception behavior. All animals received a final total volume of 45 µl of solutions into 
TMJ.  After TMJ injection of formalin, nociceptive behavioral responses were evaluated 
during a 45-min observation period. At the conclusion of the nociceptive behavioral testing, 
animals were terminally anesthetized by isoflurane and their periarticular tissue and 
trigeminal ganglia removed for further analyses. 
2.5.2. Role of PI3Kɣ/AKT pathway on 15d-PGJ2-induced antinociception. 
Animals were pre-treated (15 min) with an intra-TMJ injection to deliver the selective 
inhibitor of PI3Kɣ (AS605240, 30 μg/15 µl/TMJ) [31] or the selective inhibitor of AKT 
(AKT inhibitor IV, 10 μg/15 µl/TMJ) [31]. After that, 15d-PGJ2 (100 ng/15 µl/TMJ) or 
selective N-opioid receptor agonist U50,488 (30 µg/ 15 µl/ TMJ) [34] or the selective G-opioid 
receptor agonist E6264 (50 µg/15 µl/TMJ) [37] was also injected in the same TMJ. After 15 
min, 1.5% formalin (15 µl/TMJ) was injected into the TMJ ipsilaterally. All animals received 
a final total volume of 45 µl of solutions into TMJ. After TMJ injection of formalin, 
nociceptive behavior responses were evaluated during a 45-minute observation period.  
2.5.3. Effect of 15d-PGJ2 on expression of GRK3 and β-arrestin. Animals were 
first treated with an intra-TMJ injection of 15d-PGJ2 (100 ng/15µl/TMJ) or the selective N-
opioid receptor agonist U50,488 (30 µg/ 15 µl/ TMJ) or the selective G-opioid receptor 
agonist E6264 (10 µg/15 µl/TMJ). After 15 min, 1.5% formalin (15 µl/TMJ) was delivered 
into the TMJ ipsilaterally. All animals received a final volume of 45 µl of solutions into TMJ. 
After lapse of 45 min following formalin injection, animals were terminally anesthetized and 
the trigeminal ganglia were collected for western blot analysis.  
 2.5.4. Release of dynorphin and β-endorphin and the role of leukocytes 
cells in the 15d-PGJ2-induced antinociception in the TMJ. Animals were first treated with 1% 
thioglycollate (30 µl/TMJ) or vehicle (control group) [18]. After 3 days the animals were 
treated with an intra-TMJ injection of 15d-PGJ2 (100 ng/15 µl/TMJ) 15 min prior to an 
ipsilateral intra-TMJ injection of 1.5% formalin (15 µl/TMJ).  After lapse of 45 min following 
formalin injection, animals were terminally anesthetized by isoflurane. The articular cavity 
was washed with 10 µl PBS containing 1 mM EDTA (exudate) for quantification of cellular 
accumulation in tissue, and the periarticular tissues were collected for analyses by Enzyme-
Linked Immunosorbent Assay (ELISA). To confirm thioglycollate-induced tissue 
accumulation of macrophages, firstly, total leukocyte counts were performed in a Neubauer 
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chamber diluting the exudate in Türk solution 1:2 and the result was expressed as number of 
cells x 104/cavity. After that, the differential leukocytes counts were performed by preparing 
smears in a cytocentrifuge, which were stained with fast Panotic kit. The fraction of each cell 
type was calculated as the ratio of each cell type to the total number of leukocytes in the 
smear. This ratio was then multiplied by the total leulocyte counts obtained via Neubauer 
chamber to obtain the number of each cell type per cavity [38]. 
2.5.5. Protein extraction from TMJ periarticular tissue and trigeminal ganglia. 
Periarticular tissue and trigeminal ganglia were homogenized in 500 µl of the appropriate 
buffer containing protease inhibitors (Ripa Lysis Buffer, Santa Cruz, Biotechnology, Dallas, 
Texas, USA) followed by centrifugation of 10 min/10,000 rpm/4 °C. The total amount of 
extracted proteins was colorimetrically measured using the micro bicinchoninic acid (BCA) 
protein assay kit (Thermo Scientific, Rockford, IL, USA). The supernatants were stored at -20 
°C until further analysis. 
2.5.6. Western Blot Analysis. Protein samples of trigeminal ganglia were separated 
on SDS/PAGE gel and transferred to nitrocellulose membranes. The membranes were 
blocked in TBS (20 mM Tris–HCl, 150 mM NaCl, and 0.1% Tween 20, pH 7,53) containing 
5% non-fat dry milk overnight at 4°C, then were rinsed six times with TBS, and then 
incubated for 2h at room temperature with specific antibodies: rabbit polyclonal to β-arrestin 
1, N-opioid receptor, G-opioid receptor (Abcam, Cambridge, MA, USA) and GRK3 (Novus 
Biological, Colorado, USA), then  the membranes were rinsed again and incubated for 1 h 
with anti-rabbit IgG peroxidase-conjugated (Vector Laboratories, Burlingame, CA, USA).  
Membranes were visualized using ECL solution (Pierce) and exposed to X-ray film (Kodak) 
in a dark room. Films were scanned into Image Quant 5.2 for analysis. To confirm uniform 
protein loading, membranes were stripped and blocked overnight at 4°C, and then incubated 
for 2h with mouse monoclonal to GAPDH (Novus Biologicals, Littleton CO, USA) followed 
by incubation for 1h with anti-mouse IgG peroxidase-conjugated (Vector Laboratories, 
Burlingame, CA, USA). Banding specificity was determined by omission of primary antibody 
from the western-blotting protocol. 
2.5.7. Measurement of endogenous opioids. Release of dynorphin and β-
endorphin from TMJ periarticular tissues was evaluated by ELISA. Dynorphin and β-
endorphin ELISA kits were purchased from Phoenix Pharmaceuticals (Burlingame, CA, 
USA) and used according to the manufacturer’s protocol. 
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2.6. Statistical analysis 
To determine if there were significant differences (P<0.05) among treatment 
groups, the data were analyzed using one-way analysis of variance (ANOVA) as appropriate, 
with post hoc contrasts using the Tukey test. Data are presented in figures as mean ± standard 
deviation. 
 
3. RESULTS 
3.1. Inhibition of PPAR-J did not reduce the antinociceptive effect produced by activated 
N- or G- opioid receptors.  
Corroborating our previous result [4, 5], peripheral administration of 15d-PGJ2 (100 ng/TMJ) 
had an antinociceptive effect on formalin-induced nociception in the TMJ (P<0.05) (Fig. 1A). 
Blocking PPARJ or N-opioid receptor or the G-opioid receptor led to abrogation of the 
antinociceptive effect of 15d-PGJ2 (Fig. 1A), suggesting involvement of PPARJ with co-
participation of N- and G-opioid receptors in this effect. In an attempt to determine the 
mechanism underlying the interaction among these receptors, another set of experiments was 
done where first the PPARJ receptor was blocked by pretreatment of animals with an intra-
TMJ injection of the PPARJ antagonist GW9662 (3 ng/TMJ), and next either the N-opioid 
receptor or the G-opioid receptor was activated using their respective agonists. Blockage of 
PPARJ did not affect the antinociceptive effect of N- or G-opioid receptor agonist (Fig. 1B and 
1C). These results suggest that PPAR-J is not involved in the anti-nociceptive effect induced 
by selective agonists of N- and G- opioid receptors in the TMJ. Collectively, this data shows 
that the antinociceptive effect of 15d-PGJ2 requires activation of PPARJ and N- and G- opioid 
receptors, however, the antinociception induced by N- and G- opioid receptors is independent 
of PPARJ activation. Because 15d-PGJ2 is a ligand for PPARJ  but not N- and G- opioid 
receptors, this data suggests that PPARJ activation via 15d-PGJ2 must lead to activation of N- 
and G- opioid receptors, which then leads to the antinociceptive effect.  
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Figure 1: Inhibition of PPAR-J did not reduce the antinociceptive effect produced by activated 
N- or G- opioid receptors. (A) Intra-TMJ injection of 15d-PGJ2 (100 ng/TMJ) significantly reduced 
the nociceptive behavior induced by 1.5% formalin (P<0.05: ANOVA, Tukey’s test, n=6). Intra-TMJ 
injection of PPAR-J antagonist GW9662 (3 ng/TMJ, n=4) or N-opioid receptor antagonist Nor-BNI 
(200 µg/TMJ, n=4) or G-opioid receptor specific inhibitor ICI (30 µg/TMJ, n=4) significantly 
decreased the antinociceptive effect of 15d-PGJ2 (100 ng/TMJ, P<0.05: ANOVA, Tukey’s test).  (B) 
Intra-TMJ injection of N-opioid receptor agonist U50,488 (30 µg/TMJ) significantly reduced the 
nociceptive behavior induced by 1.5% formalin (P<0.05: ANOVA, Tukey’s test).  Pretreatment with 
GW9662 (3, 30 and 100ng/TMJ, n=4/group) did not affect the antinociceptive effect of U50,488 
(P>0.05: ANOVA, Tukey’s test). (C) Intra-TMJ injection of G-opioid receptor agonist E6264 (10 
µg/TMJ) significantly reduced the nociceptive behavior induced by 1.5% formalin.  Pretreatment with 
GW9662 (3, 30 and 100 ng/TMJ, n=4/group) did not affect the antinociceptive effect of E6264 
(P>0.05: ANOVA, Tukey’s test).  The symbol (+) indicates nociceptive behavioral response 
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significantly greater than the vehicle group. The symbol (*) indicates nociceptive behavioral response 
significantly lower than the formalin group. The symbol (#) indicates nociceptive behavioral response 
significantly higher than the 15d-PGJ2 group (P<0.05: ANOVA, Tukey’s test).  
 
3.2. 15d-PGJ2-induced antinociception is independent of the PI3Kɣ /AKT activation.  
We previously demonstrated that the antinociceptive effect of 15d-PGJ2 in the TMJ is 
mediated by the activation of the intracellular L-Arginine/NO/cGMP/K+ATP pathway in 
primary nociceptive neurons of the TMJ [4]. Data from literature suggests that activation of 
peripheral opioid receptors in primary nociceptive neurons by morphine triggers a cascade of 
intracellular signaling events initiated by PI3Kɣ /protein kinase B (AKT), which induces an 
increase in K+ATP channel currents by the nitric oxide (NO) pathway [31]. Considering that 
our data shows that the antinociceptive effect of 15d-PGJ2 involves N- and G- opioid receptors, 
we evaluated if the activation of the intracellular L-Arginine/NO/cGMP/K+ATP pathway by 
15d-PGJ2, is also mediated by PI3Kɣ/AKT pathway. Pretreatment with an intra-TMJ injection 
of the inhibitor of PI3Kɣ (AS605240) or AKT inhibitor did not affect the 15d-PGJ2-induced 
antinociception (Fig. 2A). However, pretreatment with an intra-TMJ injection of PI3Kɣ 
inhibitor or AKT inhibitor significantly reduced the antinociceptive effect of N-opioid 
receptor agonist (U50,488) or G-receptor agonist (E6264) (Fig. 2B and 2C). Thus, although 
the antinociceptive effect of 15d-PGJ2 is mediated by intracellular L-
Arginine/NO/cGMP/K+ATP pathway on primary nociceptive neurons of TMJ [16], this effect 
is independent of PI3Kɣ /AKT activation.  
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Figure 2: 15d-PGJ2-induced antinociception is independent of the  PI3Kɣ /AKT activation. (A) 
Intra-TMJ injection of 15d-PGJ2 (100 ng/TMJ, n=4) significantly decreased the nociceptive behavior 
induced by 1.5% formalin. Co-administration of PI3Kɣ inhibitor AS605240 (30 µg/TMJ, n=4) or 
AKT inhibitor IV (10 µg/TMJ, n=4) did not affect the antinociception induced by 15d-PGJ2 (100 
ng/TMJ) in the TMJ (P>0.05: ANOVA, Tukey’s test). (B) Intra-TMJ injection of N-opioid receptor 
agonist U50,488 (30 µg/TMJ, n=4) significantly decreased the nociceptive behavior induced by 1.5% 
formalin. Co-administration of AS605240 (30 µg/TMJ, n=4) or AKT inhibitor IV (10 µg/TMJ, n=4) 
significantly inhibited the antinociception induced by U50,488 (100 ng/TMJ) in the TMJ (P<0.05: 
ANOVA, Tukey’s test). (C) Intra-TMJ injection of G-opioid receptor agonist E6264 (10 µg/TMJ, n=4) 
significantly decreased the nociceptive behavior induced by 1.5% formalin. Co-administration of 
AS605240 (30 µg/TMJ, n=4) or AKT inhibitor IV (10 µg/TMJ, n=4) significantly inhibited the 
antinociception induced by E6264 (100 ng/TMJ) in the TMJ (P<0.05: ANOVA, Tukey’s test). The 
symbol (+) indicates nociceptive behavior response significantly higher than the vehicle group. The 
symbol (*) indicates nociceptive behavior response significantly lower than the formalin group. The 
symbol (#) indicates nociceptive behavior response significantly higher than the U50,488 or E6264 
group (P<0.05: ANOVA, Tukey’s test). AS60: PI3Kɣ inhibitor AS605240; AKTi: AKT inhibitor IV. 
 
3.3. 15d-PGJ2 does not affect the expression of N- or G-opioid receptors but up-regulates 
GRK3 and β-arrestin expression.  
One mechanism by which 15d-PGJ2 could potentiate the antinociceptive effect is by up-
regulating opioid receptors. Thus we investigated the effect of 15d-PGJ2 injection into the 
TMJ on opioid receptors. Western blot analysis demonstrated that intra-TMJ treatment of 
15d-PGJ2 did not affect the expression of N- or G- opioid receptors (P>0.05) (Fig. 3A and 3B). 
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However, 15d-PGJ2 significantly increased the expression of G-protein receptor kinase type 3 
(GRK3) and β-arrestin (P<0.05) (Fig. 3C and 3D), and this increase was comparable to that 
observed when N- or G-opioid receptor agonists were injected in to the TMJ. Once activated 
by their ligands, opioid receptors are internalized and desensitized following phosphorylation 
by GRK3 and β-arrestin [39, 40]. This result thus reinforce the suggestion that the 
antinociceptive effect of 15d-PGJ2 is induced by PPAR-J activation, which then subsequently 
induces activation of opioid receptors on primary nociceptive neurons of the TMJ.  
 
 
 
Figure 3: 15d-PGJ2 does not affect the expression of N- or G-opioid receptors but up-regulates 
GRK3 and β-arrestin expression. (A), (B) Western Blot analysis of N- and δ- opioid receptor-
expression showed no statistical difference between groups that received formalin alone or 15d-PGJ2 + 
formalin (P>0.05: ANOVA, Tukey’s test). (C) Pretreatment with an intra-TMJ injection of 15d-PGJ2 
(100 ng/TMJ) or U50,488 (30 µg/TMJ) or  E6264 (10 µg/TMJ) significantly increased the expression 
of β–arrestin (P<0.05: ANOVA, Tukey’s test). (D) Pretreatment with an intra-TMJ injection of 15d-
PGJ2 (100 ng/TMJ) or N-opioid receptor agonist U50,488 (30 µg/TMJ) or G-opioid receptor agonist 
E6264 (10 µg/TMJ) significantly increased the expression of GRK3 (P<0.05: ANOVA, Tukey’s test) 
in the trigeminal ganglia. The symbol (+) indicates expression significantly higher than the 1.5% 
formalin only group (P<0.05: ANOVA, Tukey’s test). The symbol (#) indicates expression 
significantly higher than 15d-PGJ2 + formalin group (P<0.05: ANOVA, Tukey’s test) 
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3.4. 15d-PGJ2-induced antinociception is caused by the release of dynorphin and β-
endorphin opioid peptides of leukocytes cells in periarticular tissue.  
As shown above, our data suggested that N- or G-opioid receptors were being activated by 
15d-PGJ2 via activation of PPAR-J. However, 15d-PGJ2 is not a ligand of opioid receptors. 
We thus speculated that PPAR-J activation via 15d-PGJ2 might increase endogenous opioid 
peptides in the TMJ, which could then activate N- or G- opioid receptors. Indeed, treatment 
with an intra-TMJ injection of 15d-PGJ2 (100 ng/TMJ) significantly increased the release of 
dynorphin and β-endorphin in the periarticular tissue of rats (Fig. 4A and 4B). To investigate 
whether the source of opioid release induced by 15d-PGJ2 could be the result of resident 
macrophages, we tested the release of endogenous opioid peptides, dynorphin and β-
endorphin, in a group of animals presenting an increased accumulation of macrophages in the 
TMJ following treatment with intra-TMJ injection of 1% thioglycollate (30 µl/TMJ/day) for 3 
days. Intra-TMJ injection of 15d-PGJ2 (100 ng/TMJ) significantly increased the release of 
dynorphin and β-endorphin in the periarticular tissue of animals treated with thioglycollate. 
To confirm that 1% thioglycollate can induce macrophage accumulation in the periarticular 
tissue, another experiment was done and animals were treated with intra-TMJ injection of 1% 
thioglycollate. A significant increase in the number of macrophages in the TMJ than other 
cells type was found in 1% thioglycollate-treated animals as compared to animals treated with 
an intra-TMJ injection of vehicle alone (0.9% NaCl) (Fig. 4C and 4D). Besides the other 
leukocytes cells could be a role in the antinociceptive effect of 15d-PGJ2 in the TMJ tissues, 
our results strongly suggest that the principal source of opioid peptides is the resident 
macrophages cells.  
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Figure 4: 15d-PGJ2-induced antinociception is caused by the release of dynorphin and β-
endorphin opioid peptides of leukocytes cells in periarticular tissue. Intra-TMJ injection of 15d-
PGJ2 ( 100 ng/TMJ, n=4) significantly  increased  the  release of  dynorphin (A) and β-endorphin (B) 
in periarticular tissue compared with vehicle only group (n=4) (P<0.05: ANOVA, Tukey’s test). 
Pretreatment with intra-TMJ injection of 1% thioglycollate (30µl/TMJ/ 3 days) significantly  increased 
the release of dynorphin and β-endorphin in the TMJ tissue compared with 15d-PGJ2 group (P<0.05: 
ANOVA, Tukey’s test). The symbol (+) indicates values significantly higher than that vehicle group. 
The symbol (*) indicates values significantly higher than the 15d-PGJ2 group. Pretreatment with an 
intra-TMJ injection of 1% thioglycollate (n=4) significantly increased macrophage cells in the TMJ 
tissues as compared to vehicle alone (C), and the increase was higher as compared to other leukocyte 
cell populations (D). There were no significant differences among cells type from periarticular tissue 
treated with vehicle (P>0.05, n=4). The symbol (+) indicates values significantly higher than that of 
other groups (P<0.05: ANOVA, Tukey test).  
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4. DISCUSSION 
From a therapeutic perspective of treating pain, there is clinical interest in primary 
afferent neurons because they are the initial source of nociceptive impulses. The inflammatory 
stimuli or tissue injuries stimulate release of characteristic cytokine cascades, which 
ultimately trigger the release of final mediators responsible for inflammatory pain [26]. Thus, 
by finding ways to inhibit sensitization and/or excitation of these neurons, subsequent central 
events leading to pain may be prevented [27]. Treatment of TMJ pain, a common source of 
chronic orofacial pain is challenging. The data presented in this study, together with our 
previous findings indicates that 15d-PGJ2 has a potential antinociceptive and anti-
inflammatory effect on the TMJ [4, 5, and 6]. Results from this study support our hypothesis 
that PPAR-J activated by 15d-PGJ2 in TMJ-resident macrophages results in the release of 
endogenous opioid peptides by these cells, which in turn bind to N- and G-opioid receptors in 
primary sensory neurons, and these stimulate the NOS/NO/Gc/GMPc/K+ATP channel anti-
nociceptive pathway resulting in membrane hyperpolarization [4].  
Endogenous 15d-PGJ2 synthesis is a result of a series of dehydration steps of 
arachidonic acid via the cyclo-oxygenase (COX) pathway. 15d-PGJ2 is thought to be actively 
taken up by cells, to accumulate in the nucleus, and to bind to the nuclear PPAR-J [8]. Once 
activated by 15d-PGJ2, PPAR-J forms a heterodimer with the retinoid X receptor and upon 
ligand-activation binds to the PPAR-J response element in the promoter of genes to allow 
transcription. It has been well demonstrated that this natural PPAR-J ligand inhibits the 
expression of several inflammatory response genes in activated macrophages, including the 
genes encoding inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), 
gelatinase B and COX-2 [41].  
Pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and TNF-α, are central mediators 
in the inflammatory hyper-nociception process, which ultimately triggers the release of final 
mediators responsible for inflammatory pain. These final mediators, such as prostanoids or 
sympathetic amines, act directly on the nociceptors to cause hypernociception, which results 
from the lowering of threshold due to modulation of specific voltage dependent sodium 
channels [26]. We have previously shown that activation of PPAR-J in peripheral tissues by 
15d-PGJ2 has the ability to inhibit carrageenan-, PGE2- and TNF-α–induced mechanical 
inflammatory hypernociception in the rat paw [17]; and formalin, 5-hidroxitriptamine and 
rheumatoid arthritis-induced hypernociception in the TMJ of rats [4, 5, 6]. This effect shown 
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by 15d-PGJ2 in different inflammatory models was in part due to the inhibition of cytokines 
such as TNF-α, IL-1β, IL-6, IL-12, IL-18, and release of chemokines KC, CINC-1. As part of 
the inflammatory process, transendothelial migration includes the initial tethering of 
leukocytes to the vessel wall mediated by the CD11/CD18 complex, followed by the rolling 
of these cells along the endothelium, forming tight adhesion to the endothelial surface by 
intercellular adhesion molecule-1 (ICAM-1), and ultimately moving through the intercellular 
junctions into the underlying tissue [42]. These leukocytes, such as neutrophils can induce 
hypernociception. We have previously also demonstrated that 15d-PGJ2 increases expression 
of the molecule decay accelerating factor (DAF, also termed CD55), an anti-adhesive 
molecule that reduces leukocyte adhesion, which can decrease transmigration process of 
leucocytes, and thus their hyernociceptive effect [43].   
Our previous data shows that the peripheral antinociceptive effect of 15d-PGJ2 is 
dependent on PPAR-J activation with the involvement of peripheral opioid receptors in 
primary sensory neurons [4, 17], specially N- and G- opioid receptors. However, the 
mechanism that underlies the signaling of PPAR-J and opioid receptors activation is still 
unknown. In the present study, pretreatment with an intra-TMJ injection of the PPAR-J 
antagonist GW9662 abrogated 15d-PGJ2-induced antinociception in the TMJ but did not 
affect the antinociceptive effect of N- and G- opioid receptor agonists (Fig. 1). These results 
suggest that PPAR-J is important for 15d-PGJ2 antinociceptive effect, but it is not involved in 
antinociceptive effect induced by selective agonists of N- and G- opioid receptors within the 
TMJ. Thus it is possible that PPAR-J activated by 15d-PGJ2 induces antinociception in the 
TMJ mediated by the release of endogenous opioid peptides. 
  Opioid peptides derived from immune cells produce analgesia by activating opioid 
receptors in peripheral sensory nerves in inflammation. It has been demonstrated that 
peripheral endogenous opioid release seems to be responsible for the antinociceptive effect of 
different mediators such as corticotropin-releasing hormone (CRH), IL-1β and cannabinoids 
[44, 45]. The major representative opioid peptides are β-endorphin, metenkephalin and 
dynorphin. These peptides and their derivatives exhibit different affinity and selectivity for 
the µ- (β-endorphin and metenkephalin), G- (enkephalins and β-endorphin), and N- 
(dynorphin) opioid receptors [46]. Interestingly, we also found that pretreatment with 15d-
PGJ2 in the TMJ significantly increased the release of dynorphin and β-endorphin in the 
periarticular tissue (Fig. 4). 
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Opioid receptors are members of the family of seven transmembrane G-protein-
coupled receptors (GPCR). Once activated by their ligands, the activated G-protein 
dissociates into the Gα and Gβ/J subunits that activate multiple effectors, including inhibition 
of cAMP production and/or directly interacting with different ion channels in the membrane 
[27]. It has been well established that activation of peripheral opioid receptors in primary 
nociceptive neurons triggers a cascade of intracellular signaling events like NO/cGMP 
pathway [47, 48, 49, 50]. Moreover, more recently it was demonstrated that morphine-
induced peripheral antinociception is due to phosphorylation of the enzymes PI3Kɣ/Protein 
kinase B (AKT) that is accompanied by activation of neuronal nitric oxide synthase (nNOS) 
and nitric oxide (NO) production, which induces an increase in K+ATP channel currents that 
causes hyperpolarization of nociceptive neurons [31]. In agreement with these findings, our 
results demonstrated that the antinociceptive effect of N- and G- agonists also depends on the 
activation of the  PI3Kɣ/AKT pathway (Fig. 2). However, although the antinociceptive effect 
of 15d-PGJ2 depends on the activation of N- and G-opioid receptors, and subsequent activation 
of the intracellular NO/cGMP/K+ATP channel pathway in primary sensory neurons [4], we 
found that 15d-PGJ2’s anti-nociceptive effect does not depend on the  PI3Kɣ/AKT pathway 
(Fig. 2). 
After activation of opioid receptors, its Gα subunit also recruits G-protein receptor 
kinases (GRK) to the membrane, where it can phosphorylate the agonist-occupied receptor, 
leading to an increased affinity for intracellular arrestin molecules. For N- and G- opioid 
receptors, GRK3 phosphorylation initiates arrestin-dependent receptor desensitization and 
internalization [48, 49].  Our western blot analysis demonstrated that pretreatment with 15d-
PGJ2 also significantly increased the expression of GRK3 and β-arrestin in the trigeminal 
ganglia (Fig. 3) suggesting that N- and G- opioid receptors were activated and subsequently 
desensitized. These results reinforce the suggestion that the antinociceptive effect of 15d-PGJ2 
is mediated via PPAR-J activation, which further induces the activation of opioid receptors in 
primary nociceptive neurons of the TMJ.   
15d-PGJ2 is not a ligand for opioid receptors. Thus, we wanted to determine how PPAR-J 
activation by 15d-PGJ2 leads to activation of N- and G-opioid receptors.  One possible 
mechanism of N- and G-opioid receptor activation could be via the endogenous opioid 
peptides, which are natural ligands for opioid receptors. Indeed, we found significantly higher 
amounts of dynorphin and β-endorphin in the TMJ periarticular tissue. Next, in an attempt to 
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determine the source of β-endorphin and dynorphin released upon stimulation of PPAR-J by 
15d-PGJ2, we observed that increasing the recruitment of peripheral macrophages by 
administration of thioglycollate in the TMJ enhanced opioid peptide release in the 
periarticular tissue (Fig. 4). This result suggests that PPAR-J located in the TMJ-resident 
macrophage cells, upon activation by 15d-PGJ2 releases endogenous opioid peptides in the 
periarticular tissue resulting in the activation of opioid receptors in the primary sensory 
neurons within the TMJ. Supporting this idea, it has previously been demonstrated that 
activated macrophages express high levels of PPAR-J [7]. Moreover, a recent study 
demonstrated that local administration of PPAR-J agonist rosiglitazone promoted a 
phenotypic shift of infiltrating macrophages from M1 (macrophages that increase 
microbicidal activity and pronociceptive mediators) to M2 (macrophages that have 
homeostatic functions) at the inflamed sites, with increased gene induction of endogenous 
opioid proenkephalin, through an HO-1-dependent mechanism [51]. However more studies 
are necessary to conclude this hypothesis. 
In conclusion, the present study suggests that the peripheral antinociceptive effect of 
15d-PGJ2 is mediated by PPAR-J expressed in leukocytes subpopulations of opioid peptide-
containing cells, such as resident macrophages of TMJ tissues. Once activated by 15d-PGJ2, 
PPAR-J induces the release of β-endorphin and dynorphin that activate N- and G- opioid 
receptors in primary sensory neurons within the TMJ, leading to antinociception.  
 
5. Acknowledgments 
We would like to thank Dr. Harvinder Gill for english review and governmental Brazilian's 
financial support CNPq (#483988/2012), CAPES (PROEX # 1830-2010) and FAPESP (# 
2011/00683-5).  
 
Conflict of interest 
None. 
 
 
 
 
38 
 
6. REFERENCES 
[1] Cairns BE (2010) Pathophysiology of TMD pain--basic mechanisms and their 
implications for pharmacotherapy. J Oral Rehabil 37: 391-410. 
[2] Sessle BJ (2011) Peripheral and central mechanisms of orofacial inflammatory pain. 
Int Rev Neurobiol 97: 179-206.  
[3] De Rossi SS (2013) Orofacial pain: a primer. Dent Clin North Am 57: 383-392. 
[4] Pena-dos-Santos DR, Severino FP, Pereira SA, Rodrigues DB, Cunha FQ, Vieira SM, 
et al.(2009) Activation of peripheral κ/δ opioid receptors mediates 15-deoxy- Δ12, 14-
prostaglandin J2 induced-antinociception in rat temporomandibular joint. 
Neuroscience 163: 1211-1219. 
[5] Clemente-Napimoga JT, Moreira JA, Grillo R, de Melo NF, Fraceto LF, Napimoga 
MH (2012) 15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties 
into rat temporomandibular hypernociception. Life Sci 90: 944-949. 
[6] Quinteiro MS, Napimoga MH, Mesquita KP, Clemente-Napimoga JT (2012) The 
indirect antinociceptive mechanism of 15d-PGJ2 on rheumatoid arthritis-induced TMJ 
inflammatory pain in rats. Eur J Pain 16: 1106-1115. 
[7] Quinteiro MS, Napimoga MH, Macedo CG, Furtado FF, Balassini HA, Bonfante R, 
Clemente-Napimoga JT (2014) 15-deoxy-Δ12,14-prostaglandin J2 reduces albumin-
induced arthritis in temporomandibular joint of rats. Eur J Pharmacol 740:58-65. 
[8] Milne GL, Yin H, Hardy KD, Davies SS, Roberts LJ (2011)  Isoprostane generation 
and function. Chem Rev 111: 5973-5996. 
[9] Schoonjans K, Martin G, Staels B, Auwerx J (1997) Peroxisome proliferators 
activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8: 159–
166. 
39 
 
[10] Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome 
proliferator-activated receptor-gamma is a negative regulator of macrophage 
activation. Nature 391: 79-82. 
[11] Escher P, Wahli W (2000) Peroxisome proliferator-activated receptors: insight 
into multiple cellular functions. Mutat Res 448: 121–138. 
[12] Surh YJ, Na HK, Park JM, Lee HN, Kim W, Yoon IS, et al. (2011) 15-Deoxy-
Δ¹²,¹⁴-prostaglandin J₂, an electrophilic lipid mediator of anti-inflammatory and pro-
resolving signaling. Biochem Pharmacol 82: 1335-1351. 
[13] Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, et al. 
(2003) Reduction in the evolution of murine type II collagen-induced arthritis by 
treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor 
gamma. Br J Pharmacol 138: 678–688. 
[14] Shan ZZ, Masuko-Hongo K, Dai SM, Nakamura H, Kato T, Nishioka K 
(2004)  A potential role of 15-deoxy-delta (12,14)-prostaglandin J2 for induction of 
human articular chondrocyte apoptosis in arthritis. J Biol Chem 279: 37939–37950. 
[15] Kaplan JM, Cook JA, Hake PW, O'Connor M, Burroughs TJ, Zingarelli B 
(2005) 15-Deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome 
proliferator activated receptor gamma ligand, reduces tissue leukosequestration and 
15-deoxy-D12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-
induced mortality in endotoxic shock. Shock 24: 59–65. 
[16] Chima RS, Hake PW, Piraino G, Mangeshkar P, Denenberg A, Zingarelli B 
(2008) Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB 
protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med 
36: 2849–2857. 
40 
 
[17] Napimoga MH, Souza GR, Cunha TM, Ferrari LF, Clemente-Napimoga JT, 
Parada CA, et al. (2008a) 15d-prostaglandin J2 inhibits inflammatory 
hypernociception: involvement of peripheral opioid receptor. J Pharmacol Exp Ther 
324: 313–321. 
[18] Napimoga MH, Vieira SM, Dal-Secco D, Freitas A, Souto FO, Mestriner FL, 
et al. (2008b) Peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-
delta12, 14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway. 
J Immunol 180:609–617. 
[19] Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J (2005) The intracerebral 
application of the PPARgamma-ligand pioglitazone confers neuroprotection against 
focal ischaemia in the rat brain. Eur J Neurosc 22: 278–282.  
[20] Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE 
(2005) Peroxisome proliferator-activated receptor-gamma ligands reduce 
inflammation and infarction size in transient focal ischemia. Neuroscience 130: 685–
696. 
[21] Pereira MP, Hurtado O, Cárdenas A, Boscá L, Castillo J, Dávalos A, et al. 
(2006) Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent 
neuroprotection after experimental stroke through non completely overlapping 
mechanisms. J. Cereb Blood Flow Metab 26: 218–229. 
[22] Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, et al. 
(2007) Thiazolidinedione class of peroxisome proliferator-activated receptor gamma 
agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, 
and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 320: 
1002–1012. 
41 
 
[23] McTigue DM, Tripathi R, Wei P, Lash AT(2007) The PPAR gamma agonist 
Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord 
injury. Exp. Neurol 205: 396–406. 
[24] Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL et al. 
(2007) Peroxisome proliferator-activated receptor-gamma agonists induce 
neuroprotection following transient focal ischemia in normotensive, normoglycemic as 
well as hypertensive and type-2 diabetic rodents. J Neurochem 101: 41–46. 
[25] Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, et al. (2008) 
Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain 
injury in rodents. Brain Res 1215: 218-224. 
[26] Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, et al. (2006) 
Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug 
development? Pharmacology & Therapeutics 112: 116–138. 
[27] Stein C, Machelska H (2011) Modulation of peripheral sensory neurons by the 
immune system: implications for pain therapy. Pharmacol Rev 63: 860-881.  
[28] Shah YM, Morimura K, Gonzalez FJ (2007) Expression of peroxisome 
proliferator-activated receptor-gamma in macrophage suppresses experimentally 
induced colitis. Am J Physiol Gastrointest Liver Physiol 292: G657-666. 
[29] Takahashi Y, Hasegawa-Moriyama M, Sakurai T, Inada E (2011) The 
macrophage-mediated effects of the peroxisome proliferator-activated receptor-
gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of 
neuropathic pain development. Anesth Analg 113: 398-404. 
[30] Brack A, Labuz D, Schiltz A, Rittner HL, Machelska H, Schäfer M, Reszka R, 
Stein C (2004)  Tissue monocytes/macrophages in inflammation: hyperalgesia versus 
opioid-mediated peripheral antinociception. Anesthesiology 101 (1): 204-211. 
42 
 
[31] Cunha TM, Roman-Campos D, Lotufo CM, Duarte HL, Souza GR, Verri WA 
Jr, et al. (2010) Morphine peripheral analgesia depends on activation of the  
PI3Kɣgamma/AKT/nNOS/NO/KATP signaling pathway. Proc Natl Acad Sci U S A 
107: 4442-4447. 
[32] Zimmermann M (1983) Ethical guidelines for investigations of experimental 
pain in conscious animals. Pain 16: 109-110. 
[33] Roveroni RC, Parada CA, Cecilia M, Veiga FA, Tambeli CH (2001) 
Development of a behavioral model of TMJ pain in rats: The TMJ formalin test. Pain 
94: 185–191. 
[34] Clemente JT, Parada CA, Veiga MC, Gear RW, Tambeli CH (2004) Sexual 
dimorphism in the antinociception mediated by kappa opioid receptors in the rat 
temporomandibular joint. Neurosci Lett 372:250–255. 
[35] Rosland JH (1991) The formalin test in mice: The influence of ambient 
temperature. Pain 45: 211-216. 
[36] Picolo G, Giorgi R, Cury Y (2000) Delta-Opioid receptors and nitric oxide 
mediate the analgesic effect of Crotalus durissus terrificus snake venom. Eur J 
Pharmacol 391: 55–62. 
[37] Kabli N, Cahill CM (2007) Anti-allodynic effects of peripheral delta opioid 
receptors in neuropathic pain. Pain 127: 84-93. 
[38] Dal Secco D, Moreira AP, Freitas A, Silva JS, Rossi MA, Ferreira SH, Cunha 
FQ (2006) Nitric oxide inhibits neutrophil migration by a mechanism dependent on 
ICAM-1: role of soluble guanylate cyclase. NitricOxide15:77–86. 
[39] Lowe JD, Celver JP, Gurevich VV, Chavkin C (2002) Mu-Opioid receptors 
desensitize less rapidly than delta-opioid receptors due to less efficient activation of 
arrestin. J Biol Chem 277: 15729-15735. 
43 
 
[40] Bruchas MR, Macey TA, Lowe JD, Chavkin C (2006) Kappa opioid receptor 
activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J 
Biol Chem 281: 18081-18089. 
[41] Zingarelli B, Cook JA (2005) Peroxisome proliferator-activated receptor-
gamma is a new therapeutic target in sepsis and inflammation. Shock 23: 393-399. 
[42] Mayadas TN, Cullere X (2005) Neutrophil beta2 integrins: moderators of life 
or death decisions. Trends Immunol 26: 388-395. 
[43] Napimoga MH, da Silva CA, Carregaro V, Farnesi-de-Assunção TS, Duarte 
PM, de Melo NF, et al. (2012) Exogenous administration of 15d-PGJ2-loaded 
nanocapsules inhibits bone resorption in a mouse periodontitis model. J Immunol 189: 
1043-1052. 
[44] Mousa SA, Schäfer M, Mitchell WM, Hassan AH, Stein C (1996) Local 
upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats 
with painful hindlimb inflammation. Eur J Pharmacol 311: 221-231. 
[45] Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, et al. (2005) CB2 
cannabinoid receptor activation produces antinociception by stimulating peripheral 
release of endogenous opioids. Proc Natl Acad Sci U S A 102: 3093–3098. 
[46] Zöllner C, Stein C (2007) Opioids. Handb Exp Pharmacol 177: 31-63. 
[47] Ferreira SH, Duarte ID, Lorenzetti BB (1991) The molecular mechanism of 
action of peripheral morphine analgesia: Stimulation of the cGMP system via nitric 
oxide release. Eur J Pharmacol 201: 121–122. 
[48] Amarante LH, Duarte ID (2002) The kappa-opioid agonist (+/-) - bremazocine 
elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic 
GMP pathway. Eur J Pharmacol 454: 19–23. 
44 
 
[49] Leánez S, Hervera A, Pol O (2009) Peripheral antinociceptive effects of mu- 
and delta opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic 
inflammatory pain. Eur J Pharmacol 602: 41–49. 
[50] Clemente-Napimoga JT, Pellegrini-da-Silva A, Ferreira VH, Napimoga MH, 
Parada CA, Tambeli CH (2009) Gonadal hormones decrease temporomandibular joint 
kappa-mediated antinociception through a down-regulation in the expression of kappa 
opioid receptors in the trigeminal ganglia. Eur J Pharmacol  617: 41-47. 
[51] Hasegawa-Moriyama M, Kurimoto Tae, Nakama M, Godai K, Kojima M, 
Kuwaki T, Kanmura Y (2013) Peroxisome proliferator-activated receptor-gamma 
agonist rosiglitazone attenuates inflammatory pain through the induction of heme 
oxygenase-1 in macrophages. Pain 154: 1402-1412. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
2.2 Microneedles enhance antinociceptive effect of topical 15d-PGJ2 cream in a rat 
model of temporomandibular joint pain. 
 
Cristina G. Macedo1; Amit K. Jain2; Michelle FranzMontan1; Marcelo H. Napimoga3; Juliana 
T. Clemente-Napimoga1; Harvinder S. Gill2 
1Piracicaba Dental School/University of Campinas, Piracicaba, São Paulo, Brazil;  
2Department of Chemical Engineering, Texas Tech University, Lubbock, Texas, USA; 
3Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and 
Research Center, Campinas, SP, Brazil.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nota: Estudo realizado na Texas Tech University sob a supervisão do Dr. Harvinder S. Gill 
no Programa de Doutorado Sanduíche no Exterior (PDSE) Processo 002316/2014-05- 
CAPES 
46 
 
ABSTRACT 
    Temporomandibular Disorders (TMDs) are related with multifactorial etiology and 
manifest through varied symptomatology. The pain arising from TMDs is often treated with 
opioids and agents that inhibit the immune response and are associated with substantial 
adverse effects and long-term risks. Thus, the development of new therapies that are safer and 
more effective is of great interest to patients and clinicians. Therefore, this study aimed to 
evaluate whether the antinociceptive effect of topically-applied 15d-PGJ2 cream can be 
enhanced with microneedles (MNs) in a rat temporomandibular joint (TMJ) model.  Efficacy 
of MNs to increase drug penetration through skin was assessed by applying of 15d-PGJ2 in a 
cream base on TMJ skin surface either after hair removal, and creating micropores in skin by 
applying stainless steel MNs patches. Animal’s nociceptive behavior was observed during a 
45 minute-period after formalin injection, and then they were euthanized and their 
periarticular tissue was removed to evaluate the release of TNF-α and IL-1β. Our findings 
demonstrated that the topical application of 15d-PGJ2 cream for 15 min did not induce any 
significant antinociceptive effect compared to direct TMJ injection of 15d-PGJ2. However, 
when TMJ skin was first treated with MNs and then cream was applied, a significant  
reduction in formalin-induced nociceptive behavior was observed compared to rats that 
received no 15d-PGJ2, and importantly this antinociceptive effect was comparable to the intra-
TMJ injection of 15d-PGJ2. A concentration-dependent effect was observed. Furthermore, the 
antinociceptive effect of 15d-PGJ2 with MN treatment persisted up to 8 h (compared to 
negative control); on the other hand direct intra-articular injection of 15d-PGJ2 was not able to 
maintain the antinociceptive effect for more than 2 h.  The 15d-PGJ2 cream associated with 
MNs also significantly reduced the release of TNF-α and IL-1β, up to 8 h. Our findings 
suggest that the 15d-PGJ2 cream associated with MNs provides antinociceptive and anti-
inflammatory effect, and can offer a potential patient-friendly therapeutic option for pain 
control related to inflammatory disorders of TMJ. 
Key words: microneedles, transdermal application, anti-inflammatory, PGJ2, prostaglandin, 
TMJ, nociception. 
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1. INTRODUCTION 
Temporomandibular Disorder (TMD) is a term generally applied to conditions 
characterized by pain and/or dysfunction in the temporomandibular joint (TMJ) and 
masticatory muscles. Its characterization has been difficult because of the large number of 
symptoms and signs attributed to this disorder [Cooper and Kleinberg, 2007]. Pain control is 
the first objective in the treatment of TMD. 
Pain is one of the classic signs of inflammatory process showing as common 
denominator the nociceptive primary afferent receptors awareness. As a result of 
inflammatory stimuli or tissue damage, the release of cytokines and chemokines pro-and anti-
inflammatory drugs trigger the release of prostanoids or sympathetic amines that act directly 
on the nociceptors to cause hypernociception, which results from the lowering of threshold 
due to modulation of specific voltage dependent sodium channels [Verri et al, 2006].   
The natural evolution of pain is the remission; however, due to the activation of 
numerous neuronal pathways of extended mode, the character of the pain can change evolving 
in many cases to the chronicity. The chronic pain affects, around the world, about 100 million 
people and approximately 14% of chronic pain is related to joints and skeletal muscle system 
[Gagliese and Melzack, 2003] and it is a serious public health problem, and can have 
consequences on patients ' quality of life. Various treatments and new therapeutic modalities 
are being studied in order to minimize the chronic pain, but the treatment of patients with this 
context has proven a challenge for health professionals. 
The pain arising from TMD conditions is often treated with opioids and agents that 
inhibit the immune response, such as corticosteroids, or modulators of the inflammatory 
cascade, for example nonsteroidal anti-inflammatory drugs [Hersh et al., 2008]. These drugs 
are associated with substantial adverse effects and risks with long-term use. The benefit of 
peripheral analgesia is targeted analgesia at the site of inflammation, and thus avoidance of 
side effects. 
15-deoxy'-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin (PG) 
that is formed following the dehydration and isomerization of PGJ2, a metabolite of PGD2. 
The presence of αβ-unsaturated carbonyl functionalities in the 15d-PGJ2 molecule contribute 
to a wide array of biological activities in many cellular systems [Milne et al., 2011] and is  a 
pharmacological agent to alleviate TMJ pain in a rat model [Quinteiro et al., 2014; Clemente-
Napimoga et al., 2012; Quinteiro e al., 2012; Pena-dos-Santos et al., 2009]. Some of the 
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known biological activities of 15d-PGJ2 are related to the observation that this compound 
activates peroxisome proliferator activated receptor-J (PPAR-J) [Ricote et al., 1998; 
Schoonjans et al., 1997]. PPAR-J is a member of the nuclear receptor superfamily and a 
ligand-activated transcription factor [Escher & Wahli, 2000] with pleiotropic effects [Surh et 
al., 2011].  
Transdermal delivery represents an attractive alternative to oral delivery of drugs and 
is poised to provide an alternative to hypodermic injection too [Praunitz & Langer, 2008]. The 
skin is an attractive area attributable to its prevalence and ease of access. The main barrier to 
the supply of drugs is the outermost layer of the skin, the stratum corneum (SC) and because 
of this barrier most of the compounds are administered with a hypodermic needle [Walter et 
al., 2010].  On the other hand injections can present some disadvantages such as: pain, needle 
phobia, transmission of infectious diseases through the reuse of needles and unintentional 
injuries [Prausnitz & Langer, 2008]. As a result, various methods have been explored to 
improve the transport of drugs through the skin. 
An additional alternative for skin permeation promotion breaking the stratum corneum 
barrier is the use of microneedles (MNs), which are projections of up to 700 µm in length, 
arranged in a patch, which can be manufactured in silicone, metal, stainless steel or titanium. 
Their use caused significant improvement on transdermal delivery, being an important 
alternative to administration of the drug for oral and hypodermic injections [Prausnitz et al., 
2004; Gill & Prausnitz, 2007a; Prausnitz & Langer, 2008]. The advantages associated with 
the use of MNs are safe, painless procedure, efficiency, ease of delivery of large molecules, 
ease of administration, potentially increasing the effectiveness of the drug due to dose 
reduction, and good tolerance without promoting edema or erythema [Prausnitz et al., 2004; 
Bariya et al., 2012]. Therefore, we propose evaluate the antinociceptive and anti-
inflammatory effect of 15d-PGJ2 in transdermal delivery system considering administer drugs 
in a safe and effective manner. 
 
2. MATERIALS AND METHODS 
2.1 Animals 
This study was carried out with male Wistar rats (6 to 8 weeks old), housed (2 per cage) in a 
temperature-controlled room (23 ± 1°C) on a 12:12 light cycle, with food and water available 
ad libitum. All animal experimental procedures and protocols were approved by the Texas 
Tech University - Animal Care and Use Committee (IACUC) under the number 14040-05. 
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2.2. Material and reagents 
 The  MNs patches measuring 1 cm x 1 cm with 57 MNs were fabricated from 50 μm-
thick stainless steel (SS316) sheets using a wet etching process described previously [Gill and 
Prausnitz, 2007b].  The 15d-PGJ2, was obtained from Calbiochem (San Diego, CA, USA). 
Formalin solution was prepared from commercially available stock formalin (an aqueous 
solution of 37% formaldehyde, obtained from Sigma-Aldrich,St. Louis, MO, USA) further 
diluted in 0.9% NaCl to a concentration of 1.5%. The cream base used was an commercial 
ambiphillic emollient cream (Unghentum) containing purified water, white soft paraffin, 
cetostearyl alcohol, polysorbate 40, propylene glycol, liquid paraffin, glycerol monostearate 
40-50, medium chain triglycerides, sorbic acid, colloidal anhydrous silica, and sodium 
hydroxide. 
 
2.3. General Procedures  
2.3.1. MNs application  
After habituation, the rats were anesthetized by isoflurane inhalation. Then, the skin of the rat 
in the right TMJ was scraped with a trimmer. After that, it was applied a solution in the TMJ 
region trimmed to complete removal of hair. The hair removal was made 1-2 days before the 
application of MNs.  This time interval of 1-2 days is conducted to ensure that the hair 
removal process does not interfere in behavioral assessment. The MNs were fixed in a Falcon 
tube (fig.1A), and applied on rats TMJ region with light pressure during 5 minutes (fig.1B and 
C). Then they were removed and discarded and the formation of micropores confirmed the 
efficiency of the application (fig.2A and B).  
 
 
Fig.1 Standardize the form of application 
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Fig.2 Micropores in TMJ region 
 
2.3.3. Cream application 
Rats were anesthetized by inhalation of isoflurane and had different concentrations of 15d- 
PGJ2 (100, 200 and 500 ng) cream applied on TMJ region.  A group of animals (n=4) 
received a control cream containing the vehicle. Each application consisted of 10 mg of cream 
which the 15d-PGJ2 was added and mixed gently. Thus the cream was applied lightly over the 
skin with the help of a plastic spatula until the complete disappearance. This caution was to 
prevent the animals from licking off the drug. 
 
2.3.2. TMJ injections 
Rats were briefly anesthetized by inhalation of isoflurane and a 30-gauge needle was 
introduced into the TMJ at the moment of injection (fig.3). A cannula consisting of a 
polyethylene tube was connected to the needle and also to a Hamilton syringe (50 µl). Each 
rat regained consciousness approximately 30 s after discontinuing the anesthetic (Roveroni et 
al., 2001). In order to keep the volume injected into TMJ the same in all experiments, animals 
received a final volume of 45 µl into TMJ as previously described (Roveroni et al., 2001). 
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                         Fig.3 Injection in the TMJ 
 
2.3.4. Testing procedure for TMJ pain 
Nociceptive behavioral testing was performed during the light phase (between 9:00 AM and 
5:00 PM) in a quiet room maintained at 23°C [Rosland, 1991]. Before the experiments, each 
animal was manipulated for 7 days to habituate them to the experimental manipulation. On 
the day of the experiment, each animal was individually placed in a test chamber (30 x 30 x 
30 cm wooden chamber lined with mirrors on the inside on all side, with clear glass on the 
front side) for a 15-min habituation period to minimize stress. After the TMJ injection, the 
animals were immediately returned to the test chamber for counting the behavioral 
nociceptive responses during a 45-min observation period. This response was defined as the 
cumulative total number of seconds that the animal spent rubbing the orofacial region 
asymmetrically with the ipsilateral fore or hind paw plus the number of head flinches counted 
during the observation period. Since head flinches followed a uniform pattern of 1 second of 
duration, each flinch was expressed as 1 second.  The recording time was divided into 9 
blocks of 5 minutes [Clemente et al., 2004; Roveroni et al., 2001].  
 
2.4. Experimental Design 
2.4.1. To evaluate that MNs application do not induces nociception in TMJ.  Groups of rats 
(4-6 per group) were treated with MNs or 0.9% NaCl injection (vehicle). A positive control 
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group received an intra-TMJ injection of 15d-PGJ2 (100 ng/TMJ) 15 min or 2 hours prior an 
ipsilateral intra-TMJ injection of 1.5% formalin, a nociceptive stimulant. The negative control 
group received no15d-PGJ2 treatment.   
2.4.2. Efficacy of MNs to increase drug penetration through skin. It was assessed by applying 
100, 200 or 500 ng of 15d-PGJ2 in 10 mg cream base on TMJ skin surface either after hair 
removal and creating micropores in skin by applying stainless steel MNs patches. Then 15 
min later an ipsilateral intra-TMJ injection of 1.5% formalin was done. 
2.4.3. To evaluate duration of antinociceptive effect from MN-treatment. Two concentrations 
of 15d-PGJ2 cream (200 and 500 ng) were applied and an ipsilateral intra-TMJ injection of 
1.5% formalin was done 2, 4, 6 or 8 h later. 
2.4.4. Protein extraction from TMJ periarticular tissue. After the evaluation of formalin-
induced nociception, the animals will be killed by deepening anesthesia and periarticular 
tissues removed and homogenized in 20 mM Tris (Cap-HCl, 150 mM NaCl, 1 mM 
Na2EDTA, 1 mm EGTA, 1% NP-40, 1% sodium Deoxycholate, sodium pyrophosphate (2.5 
mM, β-glycerophosphate 1 mM, 1 mM Na3VO4, 1 μg/ml leupeptin, pH 7.5). The samples 
shall be centrifuged at 10.000 rpm for 10 minutes at 4°C and the supernatant removed and 
stored at -80° C freezer.  
2.4.5. Measurement of cytokines TNF-α and IL-1β. Homogenized samples were used to 
release dosage of IL-1 β and TNF-α through the method ELISA using protocols provided by 
the manufacturer Phoenix Pharmaceuticals (Burlingame, CA, USA). 
2.5. Statistical analysis 
To determine if there were significant differences (P<0.05) among treatment groups, 
the data were analyzed using one-way analysis of variance (ANOVA) as appropriate, with 
post hoc contrasts using the Tukey test. Data are presented in figures as mean ± standard 
deviation. 
 
3. RESULTS 
 
3.1. Effect in TMJ nociception of MNs application or 15d-PGJ2 intra-articular injection. 
The results showed that MN was unable to induce nociceptive response being compared to the 
control group (0.9% NaCl). Peripheral administration of 15d-PGJ2 (positive control) 
significantly reduced the nociceptive response induced by formalin 1.5%, suggesting a great 
analgesic effect (fig.4) The results with the MNs are according to previous studies, which 
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demonstrated the facility of use, no invasive and the absence of pain at the site of application 
[Gill & Prausnitz, 2007; Kersten & Hirschberg, 2007; Azad & Rojanasakul, 2006].  
 
 
 
 
Fig. 4 Effect on TMJ nociception of MNs application or 15d-PGJ2 intra-articular injection. Intra-
articular injection of 1.5% formalin induced a nociceptive response significantly higher when 
compared to the response induced by intra-articular injection of 0.9% NaCl (p < 0.05; ANOVA, Tukey 
test). Pretreatment with intra-articular injection of 15 d-PGJ2 (TMJ) significantly reduced the 
nociceptive response induced by 1.5% formalin injection (p < 0.05, ANOVA, Tukey test). 
Pretreatment with MNs did not alter the nociceptive behavior when compared to the group that 
received 0.9% NaCl (p>0.05; ANOVA, Tukey test). The symbol (+) indicates nociceptive behavior 
significantly lower when compared to the 1.5% formalin group. The symbol (*) indicates behavior 
significantly higher when compared to the 0.9% NaCl group. The values are expressed by the mean ± 
SD. 
 
3.2. Effect of the MNs associated with 15d-PGJ2 cream on TMJ. 
The results showed that the three concentrations of 15d-PGJ2 (100, 200 and 500 ng) 
significantly reduced the nociceptive response induced by intra-articular injection of formalin 
in TMJ in the same way that the peripheral administration of 15d-PGJ2 by intra-articular 
injection (fig.5 A) 
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The application only of 15d-PGJ2 cream without association with the MNs in different 
concentrations (100, 200 and 500 ng) was not able to reduce the nociceptive behavior induced 
by intra-articular injection of 1.5% formalin (fig. 5 B). This result suggests that the 15d-PGJ2 
cream by itself was unable to break the SC barrier thus demonstrating the effectiveness of the 
microneedles. 
                                          
 
                                       A             
 
 
Fig. 5 (A) Effect of the MNs associated with 15d-PGJ2 cream on TMJ. Intra-articular injection of 
1.5% formalin induced a nociceptive response significantly higher when compared to the response 
induced by intra-articular injection of 0.9% NaCl (p<0.05; ANOVA, Tukey test). Pretreatment with 
the injection of 15d-PGJ2 (15min/TMJ) significantly reduced the nociceptive response induced by 
1.5% formalin injection (p<0.05; ANOVA, Tukey test). Pretreatment with MNS before the topical 
administration of 15d-PGJ2 cream (15min/100, 200 and 500 ng/TMJ significantly reduced the 
nociceptive response induced by intra-articular injection of 1.5%  formalin  (p<0.05; ANOVA, Tukey 
test). The symbol (+) indicates nociceptive behavior significantly lower when compared to the 1.5% 
formalin group. The symbol (*) indicates behavior significantly higher when compared to the 0.9% 
NaCl group. The values are expressed by the mean ± SD. 
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Fig. 5 (B) Effect of 15d-PGJ2 cream on TMJ.  Intra-articular injection of 1.5% formalin induced a 
nociceptive response significantly higher when compared to the response induced by intra-articular 
injection of 0.9% NaCl (p<0.05; ANOVA, Tukey test). Pretreatment with the injection of 15d-PGJ2 
(15min/TMJ) significantly reduced the nociceptive response by 1.5% formalin injection (p<0.05; 
ANOVA, Tukey test). The topical administration of 15d-PGJ2 cream (100, 200 and 500 
ng/15min/TMJ) was not able to reduce the nociceptive behavior induced by intra-articular injection of 
1.5% formalin (p˃0.05; ANOVA, Tukey test). The symbol (*) indicates behavior significantly higher 
when compared to the 0.9% NaCl group.  The symbol (+) indicates nociceptive behavior significantly 
lower when compared to the 1.5% formalin. The values are expressed by the mean ± SD. 
 
3.3. Duration of antinociceptive effect from MN-treatment associated with 15d-PGJ2 
cream. 
The antinociceptive effect of 200 and 500 ng 15d-PGJ2 cream with MN treatment persisted up 
to 8h (p< 0.05 compared to negative control); on the other hand direct intra-articular injection 
of 15d-PGJ2 was not able to maintain the antinociceptive effect for more than 2 h (fig. 6 A 
and B). This results suggest that the use of MNs associated with the 15d-PGJ2 cream increases 
the effectiveness and bioavailability of 15d-PGJ2 resulting in greater specificity of action of 
this drug in the trigeminal system, increasing your peripheral antinociceptive effect. 
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Fig. 6 Duration of antinociceptive effect from MN-treatment associated with 15d-PGJ2 cream. 
Intra-articular injection of 1.5% formalin induced a nociceptive response significantly higher when 
compared to the response induced by intra-articular injection of 0.9% NaCl (p<0.05; ANOVA, Tukey 
test). Pretreatment with the injection of 15d-PGJ2 (2 h/TMJ) was not able to reduce the nociceptive 
behavior induced by intra-articular injection of 1.5% formalin (p˃ 0.05, ANOVA, Tukey test). 
Pretreatment with MNs before the topical administration of 15d-PGJ2 cream (2, 4, 6 and 8 h/200  
ng/TMJ) or (2, 4, 6 and 8 h/500 ng/TMJ) significantly reduced the nociceptive response induced by 
intra-articular injection of 1.5% formalin (p<0.05; ANOVA, Tukey test). The values are expressed by 
the mean ± SD. 
 
3.4. Effect of 15d-PGJ2 cream associated with MNs on the release of TNF-α and IL1-β.  
Our results showed that the nociception induced by intra-articular injection of formalin 
significantly increases the release of TNF-α (fig.7A and B) and IL-1β (fig.8 A and B). The 
pretreatment with MNs associated with the topical use of 15d-PGJ2 cream (200 and 500 
ng/TMJ) significantly reduced the release of TNF- α (fig.7A and B) and IL-1β (fig. 8A and B) 
up to 8 h (fig.6A and B). Corroborating with other studies PPAR ligands, such as 15d-PGJ2, 
represent a promising therapeutic strategy for inflammatory diseases [Cuzzocrea et al., 2003; 
Shan et al., 2004; Kaplan et al., 2005]. Specifically the administration of 15 d-PGJ2 on rats 
TMJ has a potent analgesic and anti-inflammatory effect mediated by activation of PPAR-γ 
receptor [Pena-dos-Santos et al., 2009: Quinteiro et al., 2012; Clemente-Napimoga et al., 
2012]. 
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Fig.7 Effect 15d-PGJ2 cream associated with MNs on release of TNF-α induced by formalin in 
TMJ. (A, B) Intra-articular injection of 1.5% formalin significantly increased the release of TNF-α 
(p<0.05; ANOVA, Tukey test). The topical administration of the cream was not able to reduce the 
release of TNF-α induced by intra-articular injection of 1.5% formalin (p> 0.05, ANOVA, TUkey 
test). (A) Pretreament with mn before the topical administration of 15d-PGJ2 cream (2, 4, 6 e 8 h/ 200 
ng/TMJ) significantly reduced the release of TNF-α induced by intra-articular injection of 1.5% 
formalin in TMJ. (B) Pretreatment with mn before the topical administration of 15d-PGJ2 cream (2, 4, 
6 e 8 h/ 500 ng/TMJ) significantly reduced the release of TNF-α induced by intra-articular injection of 
1.5% formalin in TMJ. The symbol (+) indicates TNF-α release significantly less when compared to 
the 1.5% formalin group. 
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Fig. 8  Effect  of 15d-PGJ2 cream associated with MNs on release of IL1- β induced by formalin 
in TMJ. (A, B) Intra-articular injection of 1.5% formalin significantly increased the release of IL1- β 
(p<0.05; ANOVA, Tukey test). The topical administration of the cream was not able to reduce the 
release of IL1- β induced by intra-articular injection of 1.5% formalin (p> 0.05, ANOVA, TUkey test). 
(A) Pretreament with MNs before the topical administration of 15d-PGJ2 cream (2, 4, 6 e 8 h/ 200 
ng/TMJ) significantly reduced the release of IL1- β induced by intra-articular injection of 1.5% 
formalin in TMJ. (B) Pretreatment with MNs  before the topical administration of 15d-PGJ2 cream (2, 
4, 6 e 8 h/ 500 ng/TMJ) significantly reduced the release of   IL1- β induced by intra-articular injection 
of 1.5% formalin in TMJ. The symbol (+) indicates IL1- β release significantly less when compared to 
the 1.5% formalin group.  
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4. DISCUSSION 
Painful TMD involve deep tissues and has characteristics different from pain of 
cutaneous origin (Cairns, 2010). Several models have demonstrated the characteristic of 
orofacial deep-tissue pain is different from pain of cutaneous origin [Pena-dos-Santos et al., 
2009], thus developing new chemical and biological compounds intended for therapeutics is a 
great challenge for researchers (Huynh et al., 2009). 
 In this work we investigated if the antinociceptive and anti-inflammatory effect of 
15d-PGJ2 is maintained on a transdermal route using a cream base and if this effect can be 
enhanced with MNs.   
Other studies indicate that 15d-PGJ2 has a potential antinociceptive and anti-
inflammatory effect on the TMJ (Pena-dos Santos et al., 2009; Clemente-Napimoga et al., 
2012; Quinteiro et al., 2012).  In agreement with these studies, our results demonstrated the 
antinociceptive effect of 15d-PGJ2 (fig.4), however this effect was dependent of an intra-
articular injection.  
Intra-articular injections using hypodermic needles requires expertise for delivery, can 
lead to transmission of blood borne pathogens due to accidental needle sticks or intentional 
needle reuse, and causes pain, which results in reduced patient compliance due to needle 
phobia (Gill & Prausnitz, 2007). 
The application of MNs on skin is considered to be a painless and minimally invasive 
procedure compared with hypodermic injection [Gill & Prausnitz, 2007b; Bal et al., 2008; 
Gill et al., 2008]. It was demonstrated that the topical application of MNs   coated with 
different medicines such as insulin [Martanto et al., 2004] and desmopressin [Cormier et al., 
2004] increased absorption through the skin in vivo studies. These results are possible because 
the MNs are long enough to cross the barrier of the stratum corneum and deliver drugs close 
to the blood capillaries, however are short enough not to hit the pain receptors located on the 
dermal layer [Gill & Prausnitz, 2007b; Bariya et al., 2012]. In addition a recent study in 
human subjects demonstrated that therapeutic levels of naltrexone, an opioid antagonist used 
for treatment of alcohol dependence, were achieved following MN-facilitated delivery, via 
application of a naltrexone transdermal patch to MN-pretreated skin (Wermeling, et al., 
2008). 
Other studies have shown that to permit a reproducible delivery of the drug, MNs 
should be inserted into the skin in a controlled and reproducible manner (Van der Madeen et 
al., 2012; Praunitz et al., 2008).  The formation of micropores confirmed the efficiency of the 
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application (fig. 2 A and B). It is important to note that from a safety standpoint it is desirable 
for the micropores to close soon after MNs removal to prevent permeation of undesired toxic 
substances or pathogenic microbes that may lead to infection at the treatment site (Gupta et 
al., 2011). 
MNs break the barrier of SC and create pores, resulting in an increase on penetration. 
Compared with subcutaneous injection, the application of Mns allows a perforation of the 
skin without pain and provides convenient delivery of therapeutic molecules into the skin and 
may increase the permeability of the skin for many compounds, ranging in size from small 
molecules like proteins to nanoparticles loaded with drugs that typically do not penetrate the 
SC (Badran et al., 2009). 
Our findings showed that the 15d-PGJ2 cream associated with MNs had an 
antinociceptive effect up to 8 h. On the other hand only the 15d-PGJ2 cream applied topically 
was not capable to reduce the formalin-induced nociception the same form that direct intra-
articular injection of 15d-PGJ2 was not able to maintain the antinociceptive effect for more 
than 2 h. Another aspect is that 15d-PGJ2 had a high binding affinity to albumin, and 
therefore, albumin most likely acts as a carrier for 15d-PGJ2 in the circulation (Prakash et al., 
2009). Several studies have found that 15d-PGJ2 loses its biologic activity in vitro in the 
presence of serum suggesting that  15d-PGJ2 would become inactive in vivo because a large 
amount of albumin is present in the circulation (Person et al., 2001; Hagens et al., 2007). Thus 
the prevention of 15d-PGJ2 binding to albumin is using drug delivery strategies, such as 
incorporation into liposomes or conjugation to a protein carrier, might provide a novel 
strategy to improve its in vivo efficacy  and  by be a lipophilic compound and therefore can be 
incorporated into the lipid phase of liposomes (Prakash et al., 2009). 
Interaction between drugs and excipients can alter stability and bioavailability of 
drugs, thereby, affecting its safety and/or efficacy (Verma & Garg, 2005).The cream base 
used in our study may have led to a sustained release of 15d-PGJ2 as probably due the 
colloidal anhydrous silica contained in its formulation that is  frequently added to 
formulations containing lipophilic excipients to increase viscosity, prevent sedimentation 
during molding, and decrease the release rate (Tukker & De Blaey, 1984). Inorganic porous 
silica particles are mostly applied to obtain an immediate optimal drug dosage of poorly 
water-soluble compounds at the desired target site (Murillo-Cremaes et al., 2013). 
In another phase  it was assessed if these systems, in addition to increasing the 
effectiveness of 15 d-PGJ2 cream on reduced the formalin-induced nociception, also increased 
61 
 
its anti-inflammatory effect previously described (Pena-do-Santos et al., 2009; Quinteiro et 
al., 2012). For this, new experiments were performed to assess the effect of treatments with 15 
d-PGJ2 cream in the release of inflammatory mediators such as tumor necrosis factor-α (TNF-
α) and the interleukin-1 beta (IL-1 β). 
Inflammation of orofacial tissues is the most common cause of many orofacial pain 
conditions.  It is a complex biological self-defense reaction triggered by tissue damage or 
infection by pathogens. Acute inflammation is regulated by the time-and cell type-dependent 
production of cytokines and small signaling molecules including reactive oxygen species and 
prostaglandins (Reuter et al., 2010). TMJ inflammation results in the release of many pro-
inflammatory cytokines, particularly tumor necrosis factor-α (TNF-α) and interleukins 
(Leeuw, 2008) which contribute to articular cartilage remodeling and deterioration (Vernal et 
al., 2008). 
In this context, our study demonstrated that pre-treatment with MNs prior to 
application of the 15 d-PGJ2 cream promoted a significant reduction the release of 
inflammatory mediators  TNF-α and IL-1 β induced by formalin and sustaining this effect 
until 8 h after the application. A considerable amount of evidence suggests that TMJ pain may 
result from an inflammatory episode divided in two phases. The first phase is the non-
neuronal events; the resident and migrated immune cells produce a sequence of 
hypernociceptive inflammatory mediators The second phase includes the neuronal events: 
activation of receptors on primary nociceptive neurons that trigger intracellular signaling 
pathways (Kopp, 2001; Chang & Israel, 2005; Verri et al., 2006; Napimoga et al., 2008; Pena 
dos Santos et al., 2009).  The 15d-PGJ2 is produced abundantly in inflamed sites, and its 
potential role in protecting cells and tissues from acute inflammation, especially by 
facilitating the resolution of inflammation (Straus & Glass, 2001; Scher & Pillinger, 2005 and 
2009). Two molecular mechanisms are potentially involved on the proinflammatory 
properties of 15d-PGJ2, first, 15d-PGJ2 binds to the PPAR-γ that decreases the availability of 
coactivators, and thereby prevents the activity of transcription factors. Alternatively, 15d-
PGJ2 inhibits multiple steps in the NF-κB signaling pathway by PPAR- γ -independent 
mechanisms (Cheron et al., 2004). 
Although advances in understanding the scientific mechanisms involved in TMJ 
painful conditions, pain control is still a challenge for researchers, clinicians and patients. 
Thus, the development of new therapies that are safer and more effective for pain control is 
clinical and scientific relevance.  
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The results of our study suggest a less invasive treatment through transdermal route 
allied to a drug with potent anti-inflammatory and analgesic effect enhanced by MNs.  Being 
the applicability of this treatment very wide, this methodology, in addition to the treatments in 
the TMJ could be used for the treatment of different types of pain that affect the orofacial 
region and the oral cavity. 
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3 DISCUSSÃO 
A articulação temporomandibular (ATM) pode ser afetada por doenças 
inflamatórias, traumáticas, infecciosas, congênitas, do desenvolvimento e neoplásicas, como 
pode ser visto em outras articulações e algumas dessas condições são caracterizadas por dor 
e/ou disfunção (Graff-Radford e Bassiur, 2014), levando, em muitos casos, a dor orofacial 
crônica (Cairns, 2010; Sessle, 2011). A disfunção temporomandibular e dor orofacial 
aparecem com alta prevalência na população, sendo que os sinais e sintomas estão presentes 
em até 86% da população ocidental (Plesh et al., 2012). Devido ao impacto da dor de origem 
inflamatória aguda ou crônica na qualidade de vida, intensa pesquisa é direcionada para a 
descoberta de novos agentes terapêuticos para prevenir ou reverter esse processo (Mackay, 
2008). 
Dor aguda geralmente pode ser aliviada pela administração local de agentes 
farmacológicos ou abordagens não farmacológicas. Dor crônica, por outro lado, tende a ser 
uma resposta adaptativa para alguma patologia subjacente sendo a principal razão por que as 
pessoas procuram cuidados médicos, no entanto, o conjunto de fármacos eficazes disponíveis 
é limitado. Além disso, todos os analgésicos disponíveis atualmente apresentam efeitos 
colaterais associados a eles (McDougall, 2011). 
A 15d-PGJ2 difere de outras prostaglandinas, tanto quimicamente quanto 
biologicamente, em vários aspectos. Dentre as principais prostaglandinas formadas pela 
atividade da COX-2, a 15d-PGJ2 possui propriedades anti-inflamatórias (Surh et al., 2011). 
Especificamente na ATM a administração da 15d-PGJ2 apresenta um potente efeito 
analgésico e anti-inflamatório mediado pela ativação dos receptores PPAR-γ (Pena-dos-
Santos et al., 2009: Quinteiro et al., 2012; Quinteiro et al., 2014; Clemente-Napimoga et al., 
2012). 
Dentro deste contexto, nosso estudo demonstrou que PPAR-J ativado pela15d- 
PGJ2 em macrófagos residentes na ATM resultou na liberação de opióides endógenos por 
essas células, os quais por sua vez se ligam aos receptores N e G opióides em neurônios 
sensoriais primários estimulando a via do ONS/ON/Gc/GMPc/K+ATP, resultando em 
hiperpolarização da membrana e consequente efeito antinociceptivo.  
Receptores opióides regulam a atividade celular utilizando um espectro 
diversificado de vias de sinalização, incluindo adenilato ciclase (AC), fosfolipase C (PLC), 
proteína quinase C (PKC), PI3K, canais iônicos, NF-κβ, PI3K/AKT e proteína quinase 
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ativada por mitógeno (MAP) (Husain et al., 2012). Em inúmeros sistemas, a ativação do 
receptor opióide tem um efeito protetor durante situações de estresse produzido por hipóxia, 
isquemia, frio ou um ambiente ácido. Um aumento na produção e liberação de peptídeos 
opióides foi proposto como parte da resposta protetora endógena para lesões isquêmicas no 
coração e cérebro (Schultz e Gross, 2001). Além disso, alguns pesquisadores tem proposto 
que os opióides endógenos devem ser considerados como moléculas chaves que dirigem a 
atividade celular entre as respostas inflamatórias e imunológicas. Neste sentido, foi 
demonstrado que a ativação da via PI3K/AKT modula negativamente genes que promovem a 
inflamação e a permeabilidade vascular e, assim, protege a função vascular (Schabbauer, et 
al., 2004), tendo também efeito neuroprotetor através da inibição da apoptose (Fukunaga e 
Kawano, 2003). 
Corroborando esses dados, nosso estudo demonstrou que o efeito antinociceptivo 
dos agonistas dos receptores κ e δ opióides dependem da ativação da via PI3Kɣ/AKT (Art. 1, 
fig. 2). No entanto, embora o efeito antinociceptivo da 15d-PGJ2 dependa da ativação dos 
receptores N e G opióides, e subsequente ativação da via intracelular do NO/cGMP/K+ATP 
em neurônios sensoriais primários (Pena-dos-Santos et al., 2009), descobrimos que o efeito 
antinociceptivo da 15d-PGJ2 não depende da via da PI3Kɣ/AKT. 
No entanto a administração desta prostaglandina é feita por via intra-articular o 
que é invasivo, assim o desenvolvimento de formulações transdérmicas é uma estratégia 
interessante para o transporte de diversas classes de fármacos, tanto hidrofílicos quanto 
lipofílicos (Badran et al., 2009). A pele é uma área atraente devido à sua prevalência e 
facilidade de acesso. A principal barreira à entrega de drogas é a camada mais externa da pele, 
o estrato córneo (EC) e devido a essa barreira a maioria dos compostos são administrados com 
uma agulha hipodérmica (Walter et al., 2010).  Por outro lado injeções podem apresentar 
algumas desvantagens como: dor, fobia, transmissão de doenças infecciosas através da 
reutilização e lesões não intencionais (Prausnitz e Langer, 2008). Como resultado, vários 
métodos têm sido explorados para melhorar o transporte de drogas através da pele. 
Uma alternativa adicional para promoção da permeação cutânea vencendo a 
barreira do estrato córneo é o uso de microagulhas, que são projeções de no máximo 700 µm 
de comprimento, organizadas em um patch, podendo ser fabricadas em silicone, metal, aço 
inoxidável ou titânio. Seu uso tem causado significativa melhora na entrega transdérmica de 
diversos fármacos, sendo uma alternativa importante à administração por injeções 
hipodérmicas (Prausnitz et al., 2004; Gill e Prausnitz, 2007a; Prausnitz e Langer, 2008). 
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Estudos clínicos em humanos demonstraram a eficácia do uso de microagulhas 
revestidas para aplicação de vacinas (Laurent et al., 2010; Hirobe et al., 2013; Levin et al., 
2014; Norman et al., 2014), na redução de rugas (Jeon et al., 2013; Kim et al., 2014), no 
tratamento de queratose seborreica (Hiraishi et al., 2013), no tratamento de diabetes (Norman 
et al., 2013) dentre outros. 
A utilização da via transdérmica oferece vantagens em diversas circunstâncias 
quando comparada às outras vias de administração, como por exemplo, evitar o metabolismo 
de primeira passagem hepática, comum para fármacos administrados pela via oral, que é o 
responsável por diminuir a biodisponibilidade de degradar diversos fármacos (Bortolon et al., 
2008). Os fármacos de administração tópica exercem seus efeitos na periferia próximos ao seu 
sítio de aplicação estando associado ao aumento da concentração no tecido alvo e à reduzida 
concentração sérica (McCleane, 2007). 
Nossos resultados mostraram que as três concentrações do creme com 15d-PGJ2 
(100, 200 e 500 ng) associado a aplicação das microagulhas reduziu significativamente a 
resposta nociceptiva induzida pela injeção intra-articular de formalina na ATM da mesma 
maneira que a administração periférica de 15d-PGJ2 através de injeção intra-articular (Art.2, 
fig.5 A). A aplicação somente do creme de 15d-PGJ2 sem a associação com as microagulhas 
nas diferentes concentrações (100, 200 e 500 ng) não foi capaz de reduzir o comportamento 
nociceptivo induzido pela injeção intra-articular de formalina 1,5% na ATM (Art.2, fig 5 B). 
Este resultado sugere que o creme de 15d-PGJ2 por si só não foi capaz de romper o SC 
demonstrando assim a eficácia do uso das microagulhas. É importante enfatizar que foi 
possível manter a antinocicepção até oito horas após a aplicação, diferente da injeção que não 
foi capaz de reduzir o comportamento nociceptivo induzido pela formalina 1,5% além de duas 
horas da administração (Art.2, fig 6 A e B). 
Nossos resultados mostraram que utilização da microagulha associada ao creme 
com a 15d-PGJ2 aumentou a eficiência da 15d-PGJ2, resultando em uma maior especificidade 
de ação dessa droga no sistema trigeminal, aumentando seu potencial analgésico. Sugere-se 
que o creme utilizado no estudo apresentou característica de liberação prolongada do fármaco, 
uma das explicações para este efeito pode ser devido à presença de sílica coloidal anidra na 
formulação do creme. Outros estudos demonstraram que a sílica também é usada para 
estabilizar emulsões, como agente de suspensão em gel e preparações semissólidas (Daniels et 
al, 1986) e é frequentemente adicionado às formulações de supositório contendo excipientes 
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lipofílicos para aumentar a viscosidade, evitar a sedimentação durante a moldagem e diminuir 
a taxa de liberação do fármaco (Realdon et al., 1997). 
É importante salientar que a 15d-PGJ2 tem sido relatada como mediadora da 
inibição da progressão do ciclo celular e produção de citocinas em macrófagos, porém boa 
parte da 15d-PGJ2 administrada exogenamente liga-se à albumina sérica. Uma alternativa que 
atualmente tem se mostrado capaz de contornar esse problema é a liberação modificada, 
através da utilização de sistemas de liberação de fármacos. O uso de sistemas 
nanoestruturados para liberação de fármacos como lipossomas, micro e nanopartículas 
poliméricas e nanopartículas lipídicas sólidas tem sido alvo de estudo com o intuito de 
melhorar propriedades terapêuticas do fármaco a eles incorporados, levando a inúmeras 
vantagens, como o aumento da estabilidade do fármaco, liberação mais lenta e prolongada, 
diminuição da toxicidade e direcionamento a tecidos-alvo, entre outras (Napimoga et al., 
2012). 
Avaliamos em nosso estudo se, além de aumentar a eficácia antinociceptiva da 
15d-PGJ2, esse sistema associado às microagulhas também aumentavam seu efeito anti-
inflamatório previamente descrito (Pena-do-Santos et al., 2009; Quinteiro et al., 2012; 
Quinteiro et al., 2014).  
A inflamação é um conjunto de respostas do tecido características de lesão ou 
injúria. Níveis elevados de TNF- α, interleucina-1 (IL-1) e interleucina-6 (IL-6), entre outros 
mediadores pró-inflamatórios, têm sido observados em modelos animais experimentais de 
inflamação, bem como em humanos após trauma, perda de sangue severa ou sepse. O início 
da liberação desses mediadores e sua meia-vida no tecido variam significativamente, e baseia-
se nos estímulos nocivos aos quais tenha sido exposto (Azab e Kaplanski, 2001). São 
principalmente produzidas por macrófagos ativados e podem estimular, secundariamente, a 
liberação de mais citocinas (Rang et al., 2007). Neste sentido tem sido demonstrado que após 
a indução de um processo inflamatório, a TNF- α é a primeira citocina a ser liberada, de modo 
que é considerada a citocina-chave deste processo (Cunha et al., 1992). 
Nossos resultados demonstraram que a nocicepção induzida pela injeção intra-
articular de formalina aumentou significativamente a liberação de TNF-α (Art.2, fig 7 A e B) 
e IL-1β (Art.2, fig 8 A e B). O pré- tratamento com as microagulhas associadas com o uso 
tópico do creme 15d-PGJ2 (200 e 500 ng/ATM) reduziu significativamente a liberação de 
TNF- α, (Art.2, fig 7 A e B) e IL-1β (Art.2, fig 8 A e B) mantendo esse efeito por 8 h após o 
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tratamento na ATM, corroborando com os dados apresentados anteriormente de liberação 
prolongada da 15d-PGJ2.  
 Há uma correlação positiva entre dor e níveis elevados de TNF- α no líquido 
sinovial da articulação temporomandibular em pacientes com disfunção temporomandibular 
(Seadi Pereira et al., 2009). Estudos em animais demonstraram que o TNF-α induz 
hipernocicepção através de duas vias independentes e paralelas: (1) estimulando a liberação 
de IL-1β, com consequente liberação de prostanoides; e (2) através da ativação da quimiocina 
CINC-1 com consequente liberação de aminas simpatomiméticas (Verri et al., 2006). 
Em resumo, estes estudos evidenciam o potente efeito analgésico e anti-
inflamatório da 15d-PGJ2 (Figura 1) para o tratamento de condições dolorosas provenientes 
da ATM. Na Figura 1, é possível visualizar o mecanismo neuroquímico envolvido no efeito 
antinociceptivo da 15d-PGJ2 na ATM de ratos.  O uso tópico em creme da 15d-PGJ2 
associado às microagulhas pode ser uma estratégia em potencial para a administração efetiva 
e indolor da 15d-PGJ2 na ATM.  
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Figura 1– Mecanismo neuroquímico do efeito antinociceptivo da 15d-PGJ2 na ATM de 
ratos. A 15d-PGJ2 ativa PPAR (expresso em macrófago residente dos tecidos da ATM). 
Uma vez ativado pela 15d-PGJ2,  o PPAR forma um heterodímero com o receptor de ácido 
retinóide (RXR), permite a liberação de opióides endógenos que ativam receptores opióides 
(KOR e DOR) em neurônios sensoriais primários. Receptores opióides ativados por seus 
ligantes induzem mudanças conformacionais permitindo acoplamento intracelular de via 
proteína G.  As subunidades da proteína G (β/J) ativam a via antinociceptiva 
NO/cGMP/K+ATP via antinociceptiva, resultando em hiperpolarização da membrana. 
Receptores opióides são dessenssibilizados após fosforilação pelo receptor de G-proteína 
quinase tipo 3 (GRK3) e posterior ligação com β-arrestina . Como resultado da ativação de 
receptores opióides, a hiperpolarização da membrana pode inibir o sinal de quimiotaxia 
inflamatória. Além disso, a ativação PPAR-ɣ reprime a expressão de vários genes de 
resposta pró-inflamatória em macrófagos ativados, incluindo TNF-α – um mediador central 
da cascata de hipernocicepção. 
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4 CONCLUSÃO 
1. O efeito antinociceptivo da 15d-PGJ2 requer a ativação do receptor PPARJ e dos 
receptores N e G opióides, no entanto, a antinocicepção induzida pelos receptores N e G 
opióides é independente da ativação do receptor PPARJ. 
2. Embora o efeito antinociceptivo da 15D-PGJ2 é mediado pela via intracelular da L-
arginina /NO/cGMP/K+ATP em neurônios nociceptivos primários na ATM, este efeito é 
independente da ativação da PI3Kɣ/AKT.  
3.  A 15d-PGJ2 aumentou a expressão de GRK3 e β-arrestina, sugerindo que o efeito 
antinociceptivo da 15d-PGJ2 é induzido pela ativação do receptor PPAR-γ que 
posteriormente induz a ativação de receptores opióides em neurônios nociceptivos 
primários na ATM.  
4. Ativado pela 15d-PGJ2, PPAR-J induz a liberação de β-endorfina e a dinorfina que 
ativam os receptors N e G opióides em neurônios sensoriais primários na ATM, levando a 
antinocicepção. 
5.  O uso tópico do creme com 15d-PGJ2 associado à aplicação das microagulhas 
demonstrou ser um tratamento menos invasivo e com potente efeito analgésico e anti-
inflamatório. 
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